Inflammatory	inflammatory	JJ	O
bowel	bowel	NN	O
disease	disease	NN	O
IBD	IBD	NNP	O
refers	refer	VBZ	O
to	to	IN	O
a	a	DT	O
chronic	chronic	JJ	O
inflammation	inflammation	NN	O
occurring	occur	VBG	O
in	in	IN	O
the	the	DT	O
gastrointestinal	gastrointestinal	JJ	O
tract	tract	NN	O
with	with	IN	O
increasing	increase	VBG	O
worldwide	worldwide	JJ	O
incidence	incidence	NN	O
and	and	CC	O
prevalence	prevalence	NN	O
.	.	.	O

Two	two	CD	O
major	major	JJ	O
subtypes	subtype	NNS	O
of	of	IN	O
IBD	IBD	NNP	O
include	include	VBP	O
ulcerative	ulcerative	JJ	O
colitis	colitis	NN	O
UC	UC	NNP	O
and	and	CC	O
Crohnâs	crohnâs	CD	O
disease	disease	NN	O
CD	cd	NN	O
with	with	IN	O
distinct	distinct	JJ	O
injury	injury	NN	O
site	site	NN	O
and	and	CC	O
disease	disease	NN	O
types	type	NNS	O
.	.	.	O

The	the	DT	O
exact	exact	JJ	O
cause	cause	NN	O
of	of	IN	O
IBD	IBD	NNP	O
is	be	VBZ	O
not	not	RB	O
fully	fully	RB	O
understood	understand	VBN	O
,	,	,	O
but	but	CC	O
mounting	mount	VBG	O
evidences	evidence	NNS	O
suggest	suggest	VBP	O
that	that	IN	O
its	-PRON-	PRP$	O
pathogenesis	pathogenesis	NN	O
is	be	VBZ	O
associated	associate	VBN	O
with	with	IN	O
close	close	JJ	O
interactions	interaction	NNS	O
between	between	IN	O
genetic	genetic	JJ	O
,	,	,	O
immune	immune	JJ	O
,	,	,	O
and	and	CC	O
environmental	environmental	JJ	O
factors	factor	NNS	O
,	,	,	O
resulting	result	VBG	O
in	in	IN	O
impairment	impairment	NN	O
of	of	IN	O
intestinal	intestinal	JJ	O
epithelial	epithelial	JJ	O
barrier	barrier	NN	O
and	and	CC	O
dysregulation	dysregulation	NN	O
of	of	IN	O
inflammatory	inflammatory	JJ	O
cytokine	cytokine	NN	O
homeostasis	homeostasis	NN	O
.	.	.	O

While	while	IN	O
a	a	DT	O
couple	couple	NN	O
of	of	IN	O
molecular	molecular	JJ	O
targets	target	NNS	O
have	have	VBP	O
been	be	VBN	O
studied	study	VBN	O
for	for	IN	O
treatment	treatment	NN	O
of	of	IN	O
IBD	IBD	NNP	O
,	,	,	O
only	only	RB	O
a	a	DT	O
few	few	JJ	O
target	target	NN	O
-	-	HYPH	O
based	base	VBN	O
approaches	approach	NNS	O
are	be	VBP	O
successful	successful	JJ	O
and	and	CC	O
there	there	EX	O
are	be	VBP	O
no	no	DT	O
well	well	RB	O
-	-	HYPH	O
validated	validate	VBN	O
molecular	molecular	JJ	O
targets	target	NNS	O
known	know	VBN	O
so	so	RB	O
far	far	RB	O
.	.	.	O

The	the	DT	O
best	good	JJS	O
examples	example	NNS	O
of	of	IN	O
successful	successful	JJ	O
anti	anti	JJ	O
-	-	JJ	O
IBD	ibd	JJ	O
treatment	treatment	NN	O
would	would	MD	O
be	be	VB	O
anti	anti	JJ	O
-	-	JJ	O
tumour	tumour	JJ	O
necrosis	necrosis	NN	O
factor	factor	NN	O
-	-	:	O
Î±	î±	JJ	O
anti	anti	JJ	O
-	-	JJ	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
antibody	antibody	NN	O
therapies	therapy	NNS	O
such	such	JJ	O
as	as	IN	O
infliximab	infliximab	NNS	O
and	and	CC	O
adalimumab	adalimumab	NNS	O
used	use	VBN	O
in	in	IN	O
clinics	clinic	NNS	O
,	,	,	O
showing	show	VBG	O
mucosal	mucosal	NN	O
healing	healing	NN	O
in	in	IN	O
CD	cd	NN	B
.	.	.	O

However	however	RB	O
,	,	,	O
some	some	DT	O
patients	patient	NNS	O
do	do	VBP	O
not	not	RB	O
respond	respond	VB	O
to	to	IN	O
the	the	DT	O
drugs	drug	NNS	O
,	,	,	O
which	which	WDT	O
highlights	highlight	VBZ	O
the	the	DT	O
necessity	necessity	NN	O
of	of	IN	O
new	new	JJ	O
pharmacological	pharmacological	JJ	O
interventions	intervention	NNS	O
for	for	IN	O
of	of	IN	O
IBD	IBD	NNP	O
.	.	.	O

Examples	example	NNS	O
of	of	IN	O
small	small	JJ	O
molecule	molecule	NN	O
inhibitors	inhibitor	NNS	O
with	with	IN	O
good	good	JJ	O
therapeutic	therapeutic	JJ	O
outcome	outcome	NN	O
are	be	VBP	O
even	even	RB	O
scarcer	scarcer	JJ	O
.	.	.	O

A	a	DT	O
Janus	Janus	NNP	O
kinase	kinase	NN	O
JAK	JAK	NNP	O
inhibitor	inhibitor	NN	O
,	,	,	O
tofacitinib	tofacitinib	NNP	O
has	have	VBZ	O
recently	recently	RB	O
been	be	VBN	O
included	include	VBN	O
as	as	IN	O
a	a	DT	O
therapeutic	therapeutic	JJ	O
option	option	NN	O
in	in	IN	O
the	the	DT	O
treatment	treatment	NN	O
of	of	IN	O
UC	UC	NNP	O
and	and	CC	O
possibly	possibly	RB	O
of	of	IN	O
CD	cd	NN	B
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
medical	medical	JJ	O
unmet	unmet	NN	O
need	need	NN	O
for	for	IN	O
small	small	JJ	O
molecule	molecule	NN	O
IBD	IBD	NNP	O
treatment	treatment	NN	O
still	still	RB	O
remains	remain	VBZ	O
huge	huge	JJ	O
.	.	.	O

Uncontrolled	uncontrolled	JJ	O
inflammatory	inflammatory	JJ	O
response	response	NN	O
results	result	NNS	O
from	from	IN	O
an	an	DT	O
imbalance	imbalance	NN	O
between	between	IN	O
the	the	DT	O
levels	level	NNS	O
of	of	IN	O
proinflammatory	proinflammatory	JJ	O
cytokines	cytokine	NNS	O
such	such	JJ	O
as	as	IN	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
,	,	,	O
IL-6	il-6	JJ	O
,	,	,	O
IL-1Î²	IL-1Î²	NNP	O
,	,	,	O
and	and	CC	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
cytokines	cytokine	NNS	O
like	like	IN	O
IL-10	IL-10	NNP	O
and	and	CC	O
TGF	TGF	NNP	O
-	-	HYPH	O
Î²	î²	NN	B
,	,	,	B
.	.	.	O

TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
is	be	VBZ	O
a	a	DT	O
master	master	NN	O
cytokine	cytokine	NN	O
which	which	WDT	O
induces	induce	VBZ	O
the	the	DT	O
production	production	NN	O
of	of	IN	O
IL-1Î²	IL-1Î²	NNP	O
and	and	CC	O
IL-6	il-6	JJ	O
through	through	IN	O
activation	activation	NN	O
of	of	IN	O
NF	NF	NNP	O
-	-	HYPH	O
kB	kB	NNP	O
,	,	,	O
leading	lead	VBG	O
to	to	IN	O
a	a	DT	O
vicious	vicious	JJ	O
cycle	cycle	NN	O
of	of	IN	O
persistent	persistent	JJ	O
inflammation	inflammation	NN	O
and	and	CC	O
deterioration	deterioration	NN	O
of	of	IN	O
epithelial	epithelial	JJ	O
function	function	NN	B
,	,	,	B
.	.	.	O

IL-10	IL-10	NNP	O
and	and	CC	O
TGF	TGF	NNP	O
-	-	HYPH	O
Î²	Î²	NNP	O
which	which	WDT	O
downregulate	downregulate	VBP	O
proinflammatory	proinflammatory	JJ	O
cytokine	cytokine	NN	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
and	and	CC	O
IL-6	il-6	JJ	O
production	production	NN	O
and	and	CC	O
Th1	th1	NN	O
immune	immune	JJ	O
response	response	NN	O
,	,	,	O
also	also	RB	O
play	play	VB	O
a	a	DT	O
crucial	crucial	JJ	O
role	role	NN	O
in	in	IN	O
maintenance	maintenance	NN	O
of	of	IN	O
colon	colon	NN	O
mucosa	mucosa	NNS	O
integrity	integrity	NN	O
during	during	IN	O
inflammation	inflammation	NN	B
.	.	.	O

The	the	DT	O
effects	effect	NNS	O
of	of	IN	O
IL-10	IL-10	NNP	O
depend	depend	VB	O
on	on	IN	O
the	the	DT	O
timing	timing	NN	O
and	and	CC	O
sources	source	NNS	O
of	of	IN	O
its	-PRON-	PRP$	O
secretion	secretion	NN	O
.	.	.	O

In	in	IN	O
low	low	JJ	O
to	to	TO	O
moderate	moderate	JJ	O
inflammatory	inflammatory	JJ	O
condition	condition	NN	O
,	,	,	O
IL-10	IL-10	NNP	O
from	from	IN	O
dendritic	dendritic	JJ	O
cells	cell	NNS	O
or	or	CC	O
macrophages	macrophage	NNS	O
drives	drive	VBZ	O
the	the	DT	O
production	production	NN	O
of	of	IN	O
IL-10	IL-10	NNP	O
by	by	IN	O
regulatory	regulatory	JJ	O
T	t	NN	O
cells	cell	NNS	O
Treg	Treg	NNP	O
,	,	,	O
whereas	whereas	IN	O
in	in	IN	O
case	case	NN	O
of	of	IN	O
challenging	challenge	VBG	O
with	with	IN	O
strong	strong	JJ	O
proinflammatory	proinflammatory	JJ	O
response	response	NN	O
condition	condition	NN	O
,	,	,	O
a	a	DT	O
large	large	JJ	O
amount	amount	NN	O
of	of	IN	O
IL-10	IL-10	NNP	O
is	be	VBZ	O
produced	produce	VBN	O
from	from	IN	O
larger	large	JJR	O
populations	population	NNS	O
of	of	IN	O
cells	cell	NNS	O
to	to	TO	O
minimise	minimise	VB	O
pathology	pathology	NN	O
during	during	IN	O
the	the	DT	O
resolution	resolution	NN	O
phase	phase	NN	O
of	of	IN	O
the	the	DT	O
challenge	challenge	NN	B
.	.	.	O

During	during	IN	O
cellular	cellular	JJ	O
stress	stress	NN	O
or	or	CC	O
infection	infection	NN	O
,	,	,	O
an	an	DT	O
innate	innate	JJ	O
immune	immune	JJ	O
response	response	NN	O
occurs	occur	VBZ	O
through	through	IN	O
pattern	pattern	NN	O
recognition	recognition	NN	O
receptors	receptor	NNS	O
PRRs	PRRs	NNPS	O
like	like	IN	O
toll	toll	NN	O
-	-	HYPH	O
like	like	JJ	O
receptors	receptor	NNS	O
TLR	tlr	NN	O
and	and	CC	O
NOD	NOD	NNP	O
-	-	HYPH	O
like	like	JJ	O
receptors	receptor	NNS	O
.	.	.	O

NOD	NOD	NNP	O
-	-	HYPH	O
like	like	JJ	O
receptor	receptor	NN	O
protein	protein	NN	O
3	3	CD	O
NLRP3	NLRP3	NNP	O
,	,	,	O
one	one	CD	O
of	of	IN	O
the	the	DT	O
most	most	RBS	O
characterised	characterised	JJ	O
PRRs	prr	NNS	O
,	,	,	O
forms	form	VBZ	O
a	a	DT	O
multiprotein	multiprotein	NNP	O
complex	complex	NN	O
called	call	VBN	O
inflammasome	inflammasome	NN	O
,	,	,	O
leading	lead	VBG	O
to	to	IN	O
caspase-1	caspase-1	NNP	O
activation	activation	NN	O
and	and	CC	O
release	release	NN	O
of	of	IN	O
IL-1Î²	IL-1Î²	NNP	O
and	and	CC	O
IL-18	IL-18	NNP	B
.	.	.	O

NLRP3	NLRP3	NNP	O
further	further	JJ	O
triggers	trigger	VBZ	O
pyroptosis	pyroptosis	NN	O
,	,	,	O
an	an	DT	O
inflammatory	inflammatory	JJ	O
programmed	program	VBN	O
cell	cell	NN	O
death	death	NN	O
,	,	,	O
and	and	CC	O
thus	thus	RB	O
intestinal	intestinal	JJ	O
barrier	barrier	NN	O
damage	damage	NN	B
.	.	.	O

Abnormal	abnormal	JJ	O
activation	activation	NN	O
of	of	IN	O
NLRP3	NLRP3	NNP	O
inflammasome	inflammasome	NNP	O
has	have	VBZ	O
been	be	VBN	O
linked	link	VBN	O
to	to	IN	O
IBD	IBD	NNP	B
.	.	.	O

Based	base	VBN	O
on	on	IN	O
the	the	DT	O
findings	finding	NNS	O
that	that	WDT	O
inhibition	inhibition	NN	O
of	of	IN	O
NLRP3	NLRP3	NNP	O
blocks	block	VBZ	O
not	not	RB	O
only	only	RB	O
cytokine	cytokine	JJ	O
release	release	NN	O
but	but	CC	O
also	also	RB	O
pâyroptotic	pâyroptotic	VBZ	O
cell	cell	NN	O
death	death	NN	O
,	,	,	O
NLRP3	NLRP3	NNP	O
inflammasome	inflammasome	NNP	O
is	be	VBZ	O
proposed	propose	VBN	O
to	to	TO	O
be	be	VB	O
a	a	DT	O
potential	potential	JJ	O
target	target	NN	O
in	in	IN	O
IBD	IBD	NNP	O
drug	drug	NN	O
discovery	discovery	NN	O
efforts	effort	VBZ	B
.	.	.	O

For	for	IN	O
the	the	DT	O
last	last	JJ	O
several	several	JJ	O
years	year	NNS	O
,	,	,	O
we	-PRON-	PRP	O
have	have	VBP	O
conducted	conduct	VBN	O
a	a	DT	O
phenotype	phenotype	NN	O
-	-	HYPH	O
based	base	VBN	O
approach	approach	NN	O
to	to	TO	O
identify	identify	VB	O
small	small	JJ	O
molecule	molecule	NN	O
inhibitors	inhibitor	NNS	B
.	.	.	O

Based	base	VBN	O
on	on	IN	O
the	the	DT	O
notion	notion	NN	O
that	that	IN	O
immune	immune	JJ	O
cells	cell	NNS	O
such	such	JJ	O
as	as	IN	O
monocytes	monocyte	NNS	O
infiltrate	infiltrate	VBP	O
and	and	CC	O
adhere	adhere	VBP	O
to	to	TO	O
colon	colon	NN	O
epithelium	epithelium	NN	O
in	in	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
,	,	,	O
we	-PRON-	PRP	O
have	have	VBP	O
developed	develop	VBN	O
a	a	DT	O
cell	cell	NN	O
-	-	HYPH	O
based	base	VBN	O
screening	screening	NN	O
assay	assay	NN	O
to	to	TO	O
monitor	monitor	VB	O
the	the	DT	O
cell	cell	NN	O
adhesion	adhesion	NN	O
phenotype	phenotype	NN	O
in	in	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
compounds	compound	NNS	O
.	.	.	O

We	-PRON-	PRP	O
recently	recently	RB	O
published	publish	VBD	O
a	a	DT	O
couple	couple	NN	O
of	of	IN	O
papers	paper	NNS	O
on	on	IN	O
the	the	DT	O
discovery	discovery	NN	O
of	of	IN	O
6-aminopyridin-3-ols	6-aminopyridin-3-ols	CD	O
to	to	TO	O
inhibit	inhibit	VB	O
IBD	IBD	NNP	O
in	in	FW	O
vitro	vitro	FW	O
and	and	CC	O
in	in	IN	O
vivo	vivo	NNP	O
Figure	Figure	NNP	O
1	1	CD	O
.	.	.	O

Among	among	IN	O
the	the	DT	O
many	many	JJ	O
compounds	compound	NNS	O
identified	identify	VBN	O
as	as	IN	O
effective	effective	JJ	O
in	in	IN	O
the	the	DT	O
previous	previous	JJ	O
studies	study	NNS	O
,	,	,	O
the	the	DT	O
analogues	analogue	NNS	O
having	have	VBG	O
4-propylphenyl)amino	4-propylphenyl)amino	CD	O
,	,	,	O
6-chloropyridin-3-yl)amino	6-chloropyridin-3-yl)amino	CD	O
,	,	,	O
and	and	CC	O
5-phenyl-1,3,4-thiadiazol-2-yl)amino	5-phenyl-1,3,4-thiadiazol-2-yl)amino	CD	O
substructures	substructure	NNS	O
at	at	IN	O
C(6)-position	c(6)-position	NN	O
could	could	MD	O
be	be	VB	O
of	of	IN	O
particular	particular	JJ	O
excellence	excellence	NN	O
.	.	.	O

These	these	DT	O
three	three	CD	O
compounds	compound	NNS	O
showed	show	VBD	O
>	>	XX	O
75	75	CD	O
%	%	NN	O
inhibitory	inhibitory	JJ	O
effect	effect	NN	O
against	against	IN	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±-induced	î±-induce	VBN	O
cell	cell	NN	O
adhesion	adhesion	NN	O
between	between	IN	O
monocyte	monocyte	NN	O
and	and	CC	O
colon	colon	NN	O
epithelial	epithelial	JJ	O
cells	cell	NNS	O
at	at	IN	O
1âÎ¼M	1âî¼m	CD	O
concentration	concentration	NN	O
.	.	.	O

Considering	consider	VBG	O
that	that	IN	O
5-aminosalicylic	5-aminosalicylic	CD	O
acid	acid	NN	O
5-ASA	5-ASA	NNP	O
,	,	,	O
mesalazine	mesalazine	NN	O
,	,	,	O
an	an	DT	O
active	active	JJ	O
metabolite	metabolite	NN	O
of	of	IN	O
sulfasalazine	sulfasalazine	NN	O
SSZ	SSZ	NNP	O
which	which	WDT	O
is	be	VBZ	O
widely	widely	RB	O
used	use	VBN	O
to	to	TO	O
treat	treat	VB	O
IBD	IBD	NNP	O
in	in	IN	O
the	the	DT	O
clinical	clinical	JJ	O
field	field	NN	O
,	,	,	O
has	have	VBZ	O
only	only	RB	O
3.5	3.5	CD	O
%	%	NN	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
at	at	IN	O
the	the	DT	O
same	same	JJ	O
drug	drug	NN	O
concentration	concentration	NN	O
1âÎ¼M	1âî¼m	CD	O
,	,	,	O
the	the	DT	O
in	in	FW	O
vitro	vitro	FW	O
activity	activity	NN	O
of	of	IN	O
our	-PRON-	PRP$	O
three	three	CD	O
compounds	compound	NNS	O
can	can	MD	O
be	be	VB	O
quite	quite	RB	O
marvellous	marvellous	JJ	O
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
in	in	IN	O
vivo	vivo	NNP	O
efficacy	efficacy	NN	O
studies	study	NNS	O
using	use	VBG	O
rats	rat	NNS	O
with	with	IN	O
severe	severe	JJ	O
colon	colon	NN	O
inflammation	inflammation	NN	O
induced	induce	VBN	O
by	by	IN	O
2,4,6-trinitrobenzenesulfonic	2,4,6-trinitrobenzenesulfonic	CD	O
acid	acid	NN	O
TNBS	TNBS	NNP	O
have	have	VBP	O
confirmed	confirm	VBN	O
that	that	IN	O
our	-PRON-	PRP$	O
compounds	compound	NNS	O
are	be	VBP	O
certainly	certainly	RB	O
effective	effective	JJ	O
against	against	IN	O
IBD	IBD	NNP	O
.	.	.	O

When	when	WRB	O
orally	orally	RB	O
administered	administer	VBN	O
at	at	IN	O
the	the	DT	O
dose	dose	NN	O
of	of	IN	O
1âmg	1âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
,	,	,	O
those	those	DT	O
compounds	compound	NNS	O
showed	show	VBD	O
very	very	RB	O
good	good	JJ	O
efficacy	efficacy	NN	O
demonstrated	demonstrate	VBN	O
by	by	IN	O
ameliorating	ameliorating	NNP	O
disease	disease	NN	O
parameters	parameter	NNS	O
such	such	JJ	O
as	as	IN	O
%	%	NN	O
of	of	IN	O
the	the	DT	O
recovery	recovery	NN	O
in	in	IN	O
colon-	colon-	NN	O
and	and	CC	O
body	body	NN	O
-	-	HYPH	O
weights	weight	NNS	O
up	up	IN	O
to	to	TO	O
79	79	CD	O
%	%	NN	O
and	and	CC	O
59	59	CD	O
%	%	NN	O
,	,	,	O
respectively	respectively	RB	O
and	and	CC	O
myeloperoxidase	myeloperoxidase	VB	O
MPO	MPO	NNP	O
level.2,4,5-Trimethylpyridin-3-ol	level.2,4,5-Trimethylpyridin-3-ol	VBD	O
as	as	IN	O
anti	anti	JJ	O
-	-	JJ	O
IBD	ibd	JJ	O
scaffold	scaffold	NN	O
.	.	.	O

In	in	IN	O
this	this	DT	O
study	study	NN	O
,	,	,	O
we	-PRON-	PRP	O
made	make	VBD	O
some	some	DT	O
changes	change	NNS	O
in	in	IN	O
the	the	DT	O
functional	functional	JJ	O
group	group	NN	O
at	at	IN	O
C(6)-position	c(6)-position	NN	O
of	of	IN	O
the	the	DT	O
pyridin-3-ol	pyridin-3-ol	NNP	O
ring	ring	NN	O
and	and	CC	O
examined	examine	VBD	O
how	how	WRB	O
these	these	DT	O
structural	structural	JJ	O
changes	change	NNS	O
affect	affect	VBP	O
on	on	IN	O
efficacy	efficacy	NN	O
against	against	IN	O
IBD	IBD	NNP	O
.	.	.	O

We	-PRON-	PRP	O
considered	consider	VBD	O
five	five	CD	O
types	type	NNS	O
of	of	IN	O
functional	functional	JJ	O
groups	group	NNS	O
alkoxy-	alkoxy-	JJ	O
,	,	,	O
ureido-	ureido-	JJ	O
,	,	,	O
thioureido-	thioureido-	JJ	O
,	,	,	O
carbamato-	carbamato-	NNP	O
,	,	,	O
and	and	CC	O
sulfonamido	sulfonamido	NN	O
-	-	HYPH	O
group	group	NN	O
to	to	TO	O
replace	replace	VB	O
6-amino	6-amino	CD	O
groups	group	NNS	O
,	,	,	O
and	and	CC	O
synthesised	synthesise	VBD	O
several	several	JJ	O
to	to	IN	O
a	a	DT	O
dozen	dozen	NN	O
new	new	JJ	O
derivatives	derivative	NNS	O
for	for	IN	O
each	each	DT	O
family	family	NN	O
Figure	figure	NN	O
1	1	CD	O
.	.	.	O

Unless	unless	IN	O
noted	note	VBN	O
otherwise	otherwise	RB	O
,	,	,	O
materials	material	NNS	O
were	be	VBD	O
purchased	purchase	VBN	O
from	from	IN	O
commercial	commercial	JJ	O
suppliers	supplier	NNS	O
and	and	CC	O
used	use	VBN	O
without	without	IN	O
further	further	JJ	O
purification	purification	NN	O
.	.	.	O

Air-	Air-	NNP	O
or	or	CC	O
moisture	moisture	NN	O
-	-	HYPH	O
sensitive	sensitive	JJ	O
reactions	reaction	NNS	O
were	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
under	under	IN	O
an	an	DT	O
inert	inert	JJ	O
gas	gas	NN	O
atmosphere	atmosphere	NN	O
.	.	.	O

Reaction	reaction	NN	O
progress	progress	NN	O
was	be	VBD	O
monitored	monitor	VBN	O
by	by	IN	O
thin	thin	JJ	O
-	-	HYPH	O
layer	layer	NN	O
-	-	HYPH	O
chromatography	chromatography	NN	O
TLC	TLC	NNP	O
using	use	VBG	O
silica	silica	NN	O
gel	gel	VB	O
F254	F254	NNP	O
plates	plate	NNS	O
.	.	.	O

The	the	DT	O
products	product	NNS	O
were	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
flash	flash	NN	O
column	column	NN	O
chromatography	chromatography	NN	O
using	use	VBG	O
silica	silica	NNP	O
gel	gel	NNP	O
60	60	CD	O
70â230	70â230	CD	O
mesh	mesh	NN	O
or	or	CC	O
by	by	IN	O
Biotage	Biotage	NNP	O
âIsolera	âIsolera	NNP	O
Oneâ	oneâ	NN	O
system	system	NN	O
with	with	IN	O
indicated	indicate	VBN	O
solvents	solvent	NNS	O
.	.	.	O

Melting	melt	VBG	O
points	point	NNS	O
were	be	VBD	O
determined	determine	VBN	O
using	use	VBG	O
a	a	DT	O
Fischer	Fischer	NNP	O
-	-	HYPH	O
Jones	Jones	NNP	O
melting	melting	NN	O
point	point	NN	O
apparatus	apparatus	NN	O
and	and	CC	O
were	be	VBD	O
not	not	RB	O
corrected	correct	VBN	O
.	.	.	O

NMR	NMR	NNP	O
spectra	spectra	NNP	O
were	be	VBD	O
obtained	obtain	VBN	O
using	use	VBG	O
Bruker	Bruker	NNP	O
spectrometers	spectrometer	NNS	O
250âMHz	250âMHz	NNS	O
or	or	CC	O
400âMHz	400âmhz	CD	O
for	for	IN	O
1H	1H	NNP	O
-	-	HYPH	O
NMR	NMR	NNP	O
and	and	CC	O
62.5âMHz	62.5âMHz	NNP	O
or	or	CC	O
100âMHz	100âmhz	CD	O
for	for	IN	O
13âC	13âC	NNP	O
-	-	HYPH	O
NMR	NMR	NNP	O
.	.	.	O

Chemical	chemical	NN	O
shifts	shift	NNS	O
Î	Î	NNP	O
´	´	CD	O
were	be	VBD	O
expressed	express	VBN	O
in	in	IN	O
ppm	ppm	NNP	O
using	use	VBG	O
solvent	solvent	NN	O
as	as	IN	O
an	an	DT	O
internal	internal	JJ	O
standard	standard	NN	O
and	and	CC	O
coupling	couple	VBG	O
constant	constant	NN	O
J	J	NNP	O
in	in	IN	O
hertz	hertz	NNP	O
.	.	.	O

Low	low	JJ	O
-	-	HYPH	O
resolution	resolution	NN	O
mass	mass	NNP	O
spectra	spectra	NNP	O
LRMS	LRMS	NNP	O
were	be	VBD	O
obtained	obtain	VBN	O
using	use	VBG	O
an	an	DT	O
Advion	Advion	NNP	O
Expression	Expression	NNP	O
CMS	CMS	NNP	O
,	,	,	O
and	and	CC	O
recorded	record	VBD	O
in	in	IN	O
a	a	DT	O
positive	positive	JJ	O
ion	ion	NN	O
mode	mode	NN	O
with	with	IN	O
an	an	DT	O
electrospray	electrospray	NN	O
ESI	ESI	NNP	O
source	source	NN	O
.	.	.	O

Described	describe	VBN	O
below	below	RB	O
are	be	VBP	O
detailed	detailed	JJ	O
methods	method	NNS	O
for	for	IN	O
synthesising	synthesise	VBG	O
the	the	DT	O
new	new	JJ	O
compounds	compound	NNS	O
introduced	introduce	VBN	O
in	in	IN	O
this	this	DT	O
paper	paper	NN	O
.	.	.	O

Other	other	JJ	O
compounds	compound	NNS	O
were	be	VBD	O
prepared	prepare	VBN	O
using	use	VBG	O
the	the	DT	O
synthetic	synthetic	JJ	O
methods	method	NNS	O
we	-PRON-	PRP	O
had	have	VBD	O
previously	previously	RB	O
reported	report	VBN	B
.	.	.	O

To	to	IN	O
a	a	DT	O
suspension	suspension	NN	O
of	of	IN	O
10	10	CD	O
%	%	NN	O
palladium	palladium	NN	O
on	on	IN	O
activated	activate	VBN	O
carbon	carbon	NN	O
5âmg	5âmg	CD	O
in	in	IN	O
MeOH	MeOH	NNP	O
2âml	2âml	CD	O
was	be	VBD	O
added	add	VBN	O
7a	7a	IN	O
20âmg	20âmg	CD	O
,	,	,	O
0.06âmmol	0.06âmmol	NNP	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
with	with	IN	O
hydrogen	hydrogen	NN	O
balloon	balloon	NN	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
for	for	IN	O
1âh	1âh	CD	O
.	.	.	O

After	after	IN	O
filtration	filtration	NN	O
of	of	IN	O
the	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
through	through	IN	O
a	a	DT	O
Celite	Celite	NNP	O
pad	pad	NN	O
,	,	,	O
the	the	DT	O
filtrate	filtrate	NN	O
was	be	VBD	O
concentrated	concentrate	VBN	O
.	.	.	O

The	the	DT	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
silica	silica	NNP	O
gel	gel	NNP	O
column	column	NN	O
chromatography	chromatography	NN	O
CH2Cl2	CH2Cl2	NNP	O
/	/	SYM	O
MeOH	MeOH	NNP	O
=	=	SYM	O
20/1	20/1	NN	O
to	to	TO	O
give	give	VB	O
8a	8a	NNP	O
9âmg	9âmg	CD	O
,	,	,	O
98	98	CD	O
%	%	NN	O
.	.	.	O

White	white	JJ	O
solid	solid	RB	O
;	;	:	O
TLC	TLC	NNP	O
Rf	Rf	NNP	O
0.27	0.27	CD	O
CH2Cl2	CH2Cl2	NNP	O
/	/	SYM	O
MeOH	MeOH	NNP	O
=	=	SYM	O
9/1	9/1	CD	O
;	;	:	O
m.p	m.p	NNP	O
.	.	NNP	O

176âÂ	176ââ	CD	O
°	°	,	O
C	C	NNP	O
;	;	:	O
MS	MS	NNP	O
ESI	ESI	NNP	O
m	m	NNP	O
/	/	SYM	O
z	z	NNP	O
154	154	CD	O
Mâ+âH]+	mâ+âh]+	CD	O
;	;	:	O
1H	1H	NNP	O
-	-	:	O
NMR	NMR	NNP	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
Î	Î	NNP	O
´	´	CD	O
10.96	10.96	CD	O
s	s	NNP	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
7.51	7.51	CD	O
s	s	NNP	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
2.07	2.07	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
,	,	,	O
2.03	2.03	CD	O
s	s	NN	O
,	,	,	O
3H	3H	NNP	O
,	,	,	O
1.90	1.90	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
;	;	:	O
13âC	13âC	NNP	O
-	-	HYPH	O
NMR	NMR	NNP	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
Î	Î	NNP	O
´	´	CD	O
160.04	160.04	CD	O
,	,	,	O
141.97	141.97	CD	O
,	,	,	O
134.45	134.45	CD	O
,	,	,	O
126.76	126.76	CD	O
,	,	,	O
121.30	121.30	CD	O
,	,	,	O
13.70	13.70	CD	O
,	,	,	O
13.55	13.55	CD	O
,	,	,	O
12.27	12.27	CD	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
12a	12a	NNS	O
34âmg	34âmg	CD	O
,	,	,	O
0.11âmmol	0.11âmmol	NNP	O
in	in	IN	O
CH2Cl2	CH2Cl2	NNP	O
1âml	1âml	CD	O
,	,	,	O
was	be	VBD	O
added	add	VBN	O
pentamethylbenzene	pentamethylbenzene	NNP	O
50âmg	50âmg	CD	O
,	,	,	O
0.34âmmol	0.34âmmol	NNP	O
followed	follow	VBN	O
by	by	IN	O
dropwise	dropwise	NN	O
addition	addition	NN	O
of	of	IN	O
boron	boron	NN	O
trichloride	trichloride	NN	O
1âM	1âm	CD	O
in	in	IN	O
CH2Cl2	CH2Cl2	NNP	O
,	,	,	O
0.2âml	0.2âml	NFP	O
at	at	IN	O
0âÂ	0ââ	CD	O
°	°	NNS	O
C	C	NNP	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
0âÂ	0ââ	CD	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
15âmin	15âmin	NNP	O
then	then	RB	O
quenched	quench	VBN	O
with	with	IN	O
CHCl3	CHCl3	NNP	O
/	/	SYM	O
MeOH	MeOH	NNP	O
solution	solution	NN	O
9/1	9/1	CD	O
,	,	,	O
1.5âml	1.5âml	CD	O
and	and	CC	O
stirred	stir	VBN	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
for	for	IN	O
30âmin	30âmin	NNP	O
.	.	.	O

After	after	IN	O
concentration	concentration	NN	O
of	of	IN	O
the	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
,	,	,	O
2âml	2âml	CD	O
of	of	IN	O
a	a	DT	O
mixed	mixed	JJ	O
solvent	solvent	NN	O
CH2Cl2	CH2Cl2	NNP	O
/	/	SYM	O
MeOH	MeOH	NNP	O
=	=	SYM	O
40/1	40/1	NN	O
was	be	VBD	O
added	add	VBN	O
to	to	IN	O
the	the	DT	O
residue	residue	NN	O
and	and	CC	O
precipitate	precipitate	NN	O
formed	form	VBN	O
was	be	VBD	O
filtered	filter	VBN	O
,	,	,	O
washed	wash	VBN	O
with	with	IN	O
CH2Cl2	CH2Cl2	NNP	O
and	and	CC	O
collected	collect	VBN	O
to	to	TO	O
give	give	VB	O
14a	14a	NNS	O
23.6âmg	23.6âmg	NNS	O
,	,	,	O
99	99	CD	O
%	%	NN	O
.	.	.	O

White	white	JJ	O
solid	solid	RB	O
;	;	:	O
TLC	TLC	NNP	O
Rf	Rf	NNP	O
0.35	0.35	CD	O
CH2Cl2	CH2Cl2	NNP	O
/	/	SYM	O
MeOH	MeOH	NNP	O
=	=	SYM	O
9/1	9/1	CD	O
;	;	:	O
m.p	m.p	NNP	O
.	.	NNP	O

189âÂ	189ââ	CD	O
°	°	,	O
C	C	NNP	O
;	;	:	O
MS	MS	NNP	O
ESI	ESI	NNP	O
m	m	NNP	O
/	/	SYM	O
z	z	NNP	O
212	212	CD	O
Mâ+âH]+	mâ+âh]+	CD	O
;	;	:	O
1H	1H	NNP	O
-	-	:	O
NMR	NMR	NNP	O
CD3OD	CD3OD	NNP	O
Î	Î	NNP	O
´	´	CD	O
2.35	2.35	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
,	,	,	O
2.22	2.22	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
,	,	,	O
2.18	2.18	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
;	;	:	O
13âC	13âC	NNP	O
-	-	HYPH	O
NMR	NMR	NNP	O
CD3OD	CD3OD	NNP	O
Î	Î	NNP	O
´	´	CD	O
147.61	147.61	CD	O
,	,	,	O
144.33	144.33	CD	O
,	,	,	O
141.39	141.39	CD	O
,	,	,	O
137.55	137.55	CD	O
,	,	,	O
129.24	129.24	CD	O
,	,	,	O
128.91	128.91	CD	O
,	,	,	O
19.08	19.08	CD	O
,	,	,	O
12.98	12.98	CD	O
,	,	,	O
12.77	12.77	CD	O
.	.	.	O

To	to	IN	O
a	a	DT	O
suspension	suspension	NN	O
of	of	IN	O
10	10	CD	O
%	%	NN	O
palladium	palladium	NN	O
on	on	IN	O
activated	activate	VBN	O
carbon	carbon	NN	O
5âmg	5âmg	CD	O
in	in	IN	O
a	a	DT	O
mixed	mixed	JJ	O
solvent	solvent	NN	O
of	of	IN	O
MeOH	MeOH	NNP	O
2.5âml	2.5âml	NNP	O
and	and	CC	O
CH2Cl2	CH2Cl2	NNP	O
2.5âml	2.5âml	NNP	O
was	be	VBD	O
added	add	VBN	O
17a	17a	NNS	O
26âmg	26âmg	CD	O
,	,	,	O
0.08âmmol	0.08âmmol	NNP	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
with	with	IN	O
hydrogen	hydrogen	NN	O
balloon	balloon	NN	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
for	for	IN	O
1âh	1âh	CD	O
.	.	.	O

After	after	IN	O
filtration	filtration	NN	O
of	of	IN	O
the	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
through	through	IN	O
a	a	DT	O
Celite	Celite	NNP	O
pad	pad	NN	O
,	,	,	O
the	the	DT	O
filtrate	filtrate	NN	O
was	be	VBD	O
concentrated	concentrate	VBN	O
.	.	.	O

The	the	DT	O
residue	residue	NN	O
was	be	VBD	O
dissolved	dissolve	VBN	O
in	in	IN	O
MeOH	MeOH	NNP	O
and	and	CC	O
filtered	filter	VBD	O
through	through	IN	O
a	a	DT	O
membrane	membrane	NN	O
filter	filter	NN	O
and	and	CC	O
concentrated	concentrate	VBD	O
to	to	TO	O
give	give	VB	O
18a	18a	NNS	O
19âmg	19âmg	CD	O
,	,	,	O
100	100	CD	O
%	%	NN	O
.	.	.	O

Pale	pale	JJ	O
yellow	yellow	JJ	O
solid	solid	RB	O
;	;	:	O
TLC	TLC	NNP	O
Rf	Rf	NNP	O
0.2	0.2	CD	O
CH2Cl2	CH2Cl2	NNP	O
/	/	SYM	O
MeOH	MeOH	NNP	O
=	=	SYM	O
20/1	20/1	NNP	O
;	;	:	O
m.p	m.p	NNP	O
.	.	NNP	O

142âÂ	142ââ	CD	O
°	°	,	O
C	C	NNP	O
;	;	:	O
MS	MS	NNP	O
ESI	ESI	NNP	O
m	m	NNP	O
/	/	SYM	O
z	z	NNP	O
231	231	CD	O
Mâ+âH]+	Mâ+âH]+	NNP	O
;	;	:	O
1H	1H	NNP	O
-	-	:	O
NMR	NMR	NNP	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
Î	Î	NNP	O
´	´	CD	O
9.00	9.00	CD	O
s	s	NNP	O
,	,	,	O
2H	2H	NNP	O
,	,	,	O
3.20	3.20	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
,	,	,	O
2.30	2.30	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
,	,	,	O
2.11	2.11	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
,	,	,	O
2.10	2.10	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
;	;	:	O
13âC	13âC	NNP	O
-	-	HYPH	O
NMR	NMR	NNP	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
Î	Î	NNP	O
´	´	CD	O
147.22	147.22	CD	O
,	,	,	O
141.11	141.11	CD	O
,	,	,	O
140.84	140.84	CD	O
,	,	,	O
134.54	134.54	CD	O
,	,	,	O
124.95	124.95	CD	O
,	,	,	O
42.20	42.20	CD	O
,	,	,	O
19.48	19.48	CD	O
,	,	,	O
14.07	14.07	CD	O
,	,	,	O
12.69	12.69	CD	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
6-bromo-2,4,5-trimethylpyridin-3-ol	6-bromo-2,4,5-trimethylpyridin-3-ol	CD	O
3	3	CD	O
,	,	,	O
216âmg	216âmg	CD	O
,	,	,	O
1.0âmmol	1.0âmmol	CD	O
of	of	IN	O
CH3CN	CH3CN	NNP	O
10âml	10âml	CD	O
were	be	VBD	O
added	add	VBN	O
K2CO3	K2CO3	NNP	O
207âmg	207âmg	CD	O
,	,	,	O
1.5âmmol	1.5âmmol	CD	O
and	and	CC	O
iodomethane	iodomethane	NNP	O
0.12âml	0.12âml	NNP	O
,	,	,	O
2.0âmmol	2.0âmmol	CD	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
50âÂ	50âÂ	NNP	O
°	°	NNP	O
C	C	NNP	O
for	for	IN	O
16âh	16âh	CD	O
and	and	CC	O
then	then	RB	O
cooled	cool	VBD	O
to	to	TO	O
room	room	NN	O
temperature	temperature	NN	O
.	.	.	O

It	-PRON-	PRP	O
was	be	VBD	O
diluted	dilute	VBN	O
with	with	IN	O
EtOAc	EtOAc	NNS	O
and	and	CC	O
washed	wash	VBN	O
with	with	IN	O
1âM	1âm	CD	O
HCl	HCl	NNS	O
,	,	,	O
water	water	NN	O
and	and	CC	O
brine	brine	NN	O
successively	successively	RB	O
.	.	.	O

The	the	DT	O
EtOAc	EtOAc	NNS	O
solution	solution	NN	O
was	be	VBD	O
dried	dry	VBN	O
over	over	IN	O
MgSO4	MgSO4	NNP	O
,	,	,	O
filtered	filter	VBN	O
and	and	CC	O
concentrated	concentrate	VBD	O
.	.	.	O

The	the	DT	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
silica	silica	NNP	O
gel	gel	NNP	O
column	column	NN	O
chromatography	chromatography	NN	O
Hexanes	Hexanes	NNPS	O
/	/	SYM	O
EtOAc	EtOAc	NNS	O
=	=	SYM	O
9/1	9/1	LS	O
to	to	TO	O
give	give	VB	O
19	19	CD	O
154âmg	154âmg	CD	O
,	,	,	O
67	67	CD	O
%	%	NN	O
.	.	.	O

Yellow	yellow	JJ	O
oil	oil	NN	O
;	;	:	O
TLC	TLC	NNP	O
Rf	Rf	NNP	O
0.37	0.37	CD	O
Hexanes	Hexanes	NNPS	O
/	/	SYM	O
EtOAc	EtOAc	NNS	O
=	=	SYM	O
9/1	9/1	CD	O
;	;	:	O
MS	MS	NNP	O
ESI	ESI	NNP	O
m	m	NNP	O
/	/	SYM	O
z	z	NNP	O
230	230	CD	O
Mâ+âH]+	mâ+âh]+	CD	O
;	;	:	O
1H	1H	NNP	O
-	-	:	O
NMR	NMR	NNP	O
CDCl3	CDCl3	NNP	O
Î	Î	NNP	O
´	´	CD	O
3.67	3.67	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
,	,	,	O
2.44	2.44	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
,	,	,	O
2.30	2.30	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
,	,	,	O
2.24	2.24	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
;	;	:	O
13âC	13âC	NNP	O
-	-	HYPH	O
NMR	NMR	NNP	O
CDCl3	CDCl3	NNP	O
Î	Î	NNP	O
´	´	CD	O
152.76	152.76	CD	O
,	,	,	O
150.07	150.07	CD	O
,	,	,	O
141.29	141.29	CD	O
,	,	,	O
137.88	137.88	CD	O
,	,	,	O
131.95	131.95	CD	O
,	,	,	O
60.33	60.33	CD	O
,	,	,	O
18.88	18.88	CD	O
,	,	,	O
18.77	18.77	CD	O
,	,	,	O
13.50	13.50	CD	O
.	.	.	O

A	a	DT	O
solution	solution	NN	O
of	of	IN	O
20	20	CD	O
168âmg	168âmg	CD	O
,	,	,	O
0.51âmmol	0.51âmmol	NNP	O
in	in	IN	O
a	a	DT	O
mixed	mixed	JJ	O
solvent	solvent	NN	O
of	of	IN	O
THF	THF	NNP	O
/	/	SYM	O
MeOH	MeOH	NNP	O
1/10	1/10	CD	O
,	,	,	O
5.5âml	5.5âml	CD	O
was	be	VBD	O
cooled	cool	VBN	O
to	to	IN	O
0âÂ	0ââ	CD	O
°	°	,	O
C	C	NNP	O
.	.	.	O

A	a	DT	O
mixed	mixed	JJ	O
solution	solution	NN	O
of	of	IN	O
CH3COCl	CH3COCl	NNP	O
/	/	SYM	O
MeOH	MeOH	NNP	O
1/10	1/10	CD	O
,	,	,	O
1âml	1âml	CD	O
was	be	VBD	O
slowly	slowly	RB	O
added	add	VBN	O
to	to	IN	O
the	the	DT	O
mixture	mixture	NN	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
for	for	IN	O
18âh	18âh	CD	O
and	and	CC	O
then	then	RB	O
concentrated	concentrate	VBD	O
.	.	.	O

The	the	DT	O
residue	residue	NN	O
was	be	VBD	O
diluted	dilute	VBN	O
with	with	IN	O
EtOAc	EtOAc	NNS	O
and	and	CC	O
water	water	NN	O
.	.	.	O

The	the	DT	O
EtOAc	EtOAc	NNS	O
layer	layer	NN	O
separated	separate	VBN	O
was	be	VBD	O
extracted	extract	VBN	O
with	with	IN	O
water	water	NN	O
.	.	.	O

To	to	IN	O
the	the	DT	O
combined	combined	JJ	O
aqueous	aqueous	JJ	O
solution	solution	NN	O
was	be	VBD	O
added	add	VBN	O
1âM	1âm	CD	O
NaOH	NaOH	NNP	O
until	until	IN	O
the	the	DT	O
pH	pH	NNP	O
of	of	IN	O
the	the	DT	O
solution	solution	NN	O
reached	reach	VBD	O
10	10	CD	O
.	.	.	O

After	after	IN	O
extraction	extraction	NN	O
of	of	IN	O
the	the	DT	O
mixture	mixture	NN	O
with	with	IN	O
EtOAc	EtOAc	NNS	O
,	,	,	O
the	the	DT	O
EtOAc	EtOAc	NNS	O
solution	solution	NN	O
was	be	VBD	O
dried	dry	VBN	O
over	over	IN	O
MgSO4	MgSO4	NNP	O
,	,	,	O
filtered	filter	VBN	O
and	and	CC	O
concentrated	concentrate	VBD	O
.	.	.	O

The	the	DT	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
silica	silica	NNP	O
gel	gel	NNP	O
column	column	NN	O
chromatography	chromatography	NN	O
CH2Cl2	CH2Cl2	NNP	O
/	/	SYM	O
MeOH	MeOH	NNP	O
=	=	SYM	O
30/1	30/1	NN	O
to	to	TO	O
give	give	VB	O
21	21	CD	O
54âmg	54âmg	CD	O
,	,	,	O
64	64	CD	O
%	%	NN	O
.	.	.	O

Grey	Grey	NNP	O
solid	solid	JJ	O
;	;	:	O
TLC	TLC	NNP	O
Rf	Rf	NNP	O
0.15	0.15	CD	O
CH2Cl2	CH2Cl2	NNP	O
/	/	SYM	O
MeOH	MeOH	NNP	O
=	=	SYM	O
20/1	20/1	NNP	O
;	;	:	O
m.p	m.p	NNP	O
.	.	NNP	O

84âÂ	84âÂ	NNP	O
°	°	NNP	O
C	C	NNP	O
;	;	:	O
MS	MS	NNP	O
ESI	ESI	NNP	O
m	m	NNP	O
/	/	SYM	O
z	z	NNP	O
167	167	CD	O
Mâ+âH]+	mâ+âh]+	CD	O
;	;	:	O
1H	1H	NNP	O
-	-	:	O
NMR	NMR	NNP	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
Î	Î	NNP	O
´	´	CD	O
5.22	5.22	CD	O
s	s	NNP	O
,	,	,	O
2H	2H	NNP	O
,	,	,	O
3.52	3.52	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
,	,	,	O
2.17	2.17	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
,	,	,	O
2.06	2.06	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
,	,	,	O
1.91	1.91	CD	O
s	s	NNP	O
,	,	,	O
3H	3H	NNP	O
;	;	:	O
13âC	13âC	NNP	O
-	-	HYPH	O
NMR	NMR	NNP	O
CDCl3	CDCl3	NNP	O
Î	Î	NNP	O
´	´	CD	O
152.25	152.25	CD	O
,	,	,	O
146.62	146.62	CD	O
,	,	,	O
145.79	145.79	CD	O
,	,	,	O
139.72	139.72	CD	O
,	,	,	O
113.51	113.51	CD	O
,	,	,	O
60.53	60.53	CD	O
,	,	,	O
18.45	18.45	CD	O
,	,	,	O
13.05	13.05	CD	O
,	,	,	O
12.42	12.42	CD	O
.	.	.	O

RPMI-1640	rpmi-1640	NN	O
,	,	,	O
foetal	foetal	JJ	O
bovine	bovine	NN	O
serum	serum	NN	O
FBS	FBS	NNP	O
,	,	,	O
penicillin	penicillin	NN	O
/	/	SYM	O
streptomycin	streptomycin	NN	O
and	and	CC	O
trizol	trizol	NN	O
reagent	reagent	NNP	O
were	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
Invitrogen	Invitrogen	NNP	O
Life	Life	NNP	O
Technologies	Technologies	NNPS	O
Carlsbad	Carlsbad	NNP	O
,	,	,	O
CA	CA	NNP	O
,	,	,	O
USA	USA	NNP	O
.	.	.	O

Trypsin	Trypsin	NNP	O
/	/	SYM	O
EDTA	EDTA	NNP	O
was	be	VBD	O
purchased	purchase	VBN	O
from	from	IN	O
Clonetics	Clonetics	NNP	O
,	,	,	O
Inc.	Inc.	NNP	O
Walkersville	Walkersville	NNP	O
,	,	,	O
MD	MD	NNP	O
,	,	,	O
USA	USA	NNP	O
.	.	.	O

Recombinant	recombinant	JJ	O
human	human	JJ	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
was	be	VBD	O
procured	procure	VBN	O
from	from	IN	O
R	r	NN	O
&	&	CC	O
D	D	NNP	O
system	system	NN	O
Inc	Inc	NNP	O
,	,	,	O
Minneapolis	Minneapolis	NNP	O
,	,	,	O
MN	MN	NNP	O
,	,	,	O
USA	USA	NNP	O
.	.	.	O

BCECF	BCECF	NNP	O
/	/	SYM	O
AM	AM	NNP	O
acetoxymethyl	acetoxymethyl	NNP	O
ester	ester	NN	O
was	be	VBD	O
received	receive	VBN	O
from	from	IN	O
Molecular	molecular	JJ	O
probes	probe	NNS	O
Eugene	Eugene	NNP	O
,	,	,	O
Oregon	Oregon	NNP	O
,	,	,	O
USA	USA	NNP	O
.	.	.	O

Antibodies	antibody	NNS	O
directed	direct	VBD	O
against	against	IN	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
,	,	,	O
IL-1Î²	IL-1Î²	NNP	O
,	,	,	O
Claudin-2	Claudin-2	NNP	O
,	,	,	O
NLRP3	NLRP3	NNP	O
,	,	,	O
Claudin-3	Claudin-3	NNP	O
and	and	CC	O
Caspase-1	Caspase-1	NNP	O
were	be	VBD	O
purchased	purchase	VBN	O
from	from	IN	O
Abcam	Abcam	NNP	O
Cambridge	Cambridge	NNP	O
,	,	,	O
MA	MA	NNP	O
,	,	,	O
USA	USA	NNP	O
.	.	.	O

Antibodies	antibody	NNS	O
against	against	IN	O
IL-6	IL-6	NNP	O
and	and	CC	O
IL-10	IL-10	NNP	O
were	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
Abbiotec	Abbiotec	NNP	O
San	San	NNP	O
Diego	Diego	NNP	O
,	,	,	O
CA	CA	NNP	O
,	,	,	O
USA	USA	NNP	O
.	.	.	O

E	E	NNP	O
-	-	NN	O
cadherin	cadherin	NNP	O
,	,	,	O
ZO-1	ZO-1	NNP	O
,	,	,	O
IL-18	IL-18	NNP	O
and	and	CC	O
I	I	NNP	O
-	-	HYPH	O
ÎºB	ÎºB	NNP	O
antibodies	antibody	NNS	O
were	be	VBD	O
purchased	purchase	VBN	O
from	from	IN	O
Santa	Santa	NNP	O
Cruz	Cruz	NNP	O
Biotechnology	Biotechnology	NNP	O
Santa	Santa	NNP	O
Cruz	Cruz	NNP	O
,	,	,	O
CA	CA	NNP	O
,	,	,	O
USA	USA	NNP	O
while	while	IN	O
NF	NF	NNP	O
-	-	HYPH	O
ÎºB	ÎºB	NNP	O
,	,	,	O
TGFÎ²	TGFÎ²	NNS	O
and	and	CC	O
phospho	phospho	NN	O
-	-	:	O
I	I	NNP	O
-	-	HYPH	O
ÎºB	ÎºB	NNP	O
antibodies	antibody	NNS	O
were	be	VBD	O
purchased	purchase	VBN	O
from	from	IN	O
Cell	Cell	NNP	O
Signalling	Signalling	NNP	O
Technology	Technology	NNP	O
Inc.	Inc.	NNP	O
Beverly	Beverly	NNP	O
,	,	,	O
MA	MA	NNP	O
,	,	,	O
USA	USA	NNP	O
.	.	.	O

HT-29	HT-29	NNP	O
human	human	JJ	O
colonic	colonic	JJ	O
epithelial	epithelial	JJ	O
cell	cell	NN	O
line	line	NN	O
and	and	CC	O
U937	U937	NNP	O
human	human	JJ	O
pre	pre	JJ	O
-	-	JJ	O
monocytic	monocytic	JJ	O
cell	cell	NN	O
line	line	NN	O
were	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
the	the	DT	O
American	American	NNP	O
Type	Type	NNP	O
Culture	Culture	NNP	O
Collection	Collection	NNP	O
Manassas	Manassas	NNP	O
,	,	,	O
VA	VA	NNP	O
,	,	,	O
USA	USA	NNP	O
.	.	.	O

HT-29	HT-29	NNP	O
cells	cell	NNS	O
and	and	CC	O
U937	u937	NN	O
cells	cell	NNS	O
were	be	VBD	O
cultured	culture	VBN	O
in	in	IN	O
RPMI-1640	RPMI-1640	NNP	O
media	media	NN	O
containing	contain	VBG	O
10	10	CD	O
%	%	NN	O
FBS	FBS	NNP	O
,	,	,	O
100âIU	100âiu	CD	O
/	/	SYM	O
ml	ml	NN	O
of	of	IN	O
penicillin	penicillin	NN	O
and	and	CC	O
100âÎ¼g	100âÎ¼g	NNP	O
/	/	SYM	O
mL	ml	NN	O
of	of	IN	O
streptomycin	streptomycin	NN	O
.	.	.	O

Cells	cell	NNS	O
were	be	VBD	O
maintained	maintain	VBN	O
at	at	IN	O
37âÂ	37ââ	CD	O
°	°	,	O
C	C	NNP	O
in	in	IN	O
5	5	CD	O
%	%	NN	O
CO2	CO2	NNP	O
in	in	IN	O
humidifier	humidifi	JJR	O
incubator	incubator	NN	O
.	.	.	O

Adhesion	adhesion	NN	O
of	of	IN	O
monocytes	monocyte	NNS	O
to	to	TO	O
colon	colon	VB	O
epithelial	epithelial	JJ	O
cell	cell	NN	O
layer	layer	NN	O
was	be	VBD	O
measured	measure	VBN	O
by	by	IN	O
using	use	VBG	O
U937	U937	NNP	O
pre	pre	JJ	O
-	-	JJ	O
monocytic	monocytic	JJ	O
cells	cell	NNS	O
prelabeled	prelabele	VBN	O
with	with	IN	O
2â²,7â²-bis(2-carboxyethyl)-5(6)-carboxylfluorescein	2â²,7â²-bis(2-carboxyethyl)-5(6)-carboxylfluorescein	CD	O
acetoxymethyl	acetoxymethyl	NNP	O
ester	ester	NN	O
BCECF	BCECF	NNP	O
/	/	SYM	O
AM	AM	NNP	O
,	,	,	O
10âÂµg	10ââµg	CD	O
/	/	SYM	O
ml	ml	NNP	O
as	as	IN	O
previously	previously	RB	O
reported	report	VBN	B
,	,	,	B
with	with	IN	O
slight	slight	JJ	O
modification	modification	NN	O
.	.	.	O

HT-29	HT-29	NNP	O
cells	cell	NNS	O
2âÃâ105	2âãâ105	CD	O
cells	cell	NNS	O
/	/	SYM	O
well	well	UH	O
cultured	cultured	JJ	O
in	in	IN	O
48-well	48-well	CD	O
plates	plate	NNS	O
were	be	VBD	O
pre	pre	VBN	O
-	-	VBN	O
treated	treat	VBN	O
with	with	IN	O
compounds	compound	NNS	O
for	for	IN	O
1âh	1âh	CD	O
.	.	.	O

The	the	DT	O
prelabeled	prelabeled	JJ	O
U937	u937	NN	O
cells	cell	NNS	O
were	be	VBD	O
added	add	VBN	O
on	on	IN	O
the	the	DT	O
monolayer	monolayer	NN	O
of	of	IN	O
HT-29	HT-29	NNP	O
cells	cell	NNS	O
,	,	,	O
and	and	CC	O
they	-PRON-	PRP	O
were	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
10âng	10âng	CD	O
/	/	SYM	O
mL	ml	NN	O
for	for	IN	O
3âh	3âh	CD	O
at	at	IN	O
37âÂ	37ââ	CD	O
°	°	,	O
C	C	NNP	O
.	.	.	O

Non	Non	AFX	O
adhering	adhere	VBG	O
U937	u937	NN	O
cells	cell	NNS	O
were	be	VBD	O
removed	remove	VBN	O
by	by	IN	O
washing	wash	VBG	O
thrice	thrice	NN	O
with	with	IN	O
PBS	PBS	NNP	O
.	.	.	O

Cells	cell	NNS	O
were	be	VBD	O
lysed	lyse	VBN	O
with	with	IN	O
0.1	0.1	CD	O
%	%	NN	O
Triton	Triton	NNP	O
X-100	X-100	NNP	O
in	in	IN	O
Tris	Tris	NNP	O
0.1âM	0.1âM	NNP	O
,	,	,	O
and	and	CC	O
fluorescence	fluorescence	NN	O
intensity	intensity	NN	O
was	be	VBD	O
measured	measure	VBN	O
using	use	VBG	O
Fluostar	Fluostar	NNP	O
Optima	Optima	NNP	O
microplate	microplate	NN	O
reader	reader	NN	O
BMG	BMG	NNP	O
LABTECH	LABTECH	NNP	O
GmbH	GmbH	NNP	O
,	,	,	O
Germany	Germany	NNP	O
at	at	IN	O
an	an	DT	O
excitation	excitation	NN	O
and	and	CC	O
emission	emission	NN	O
wavelengths	wavelength	NNS	O
of	of	IN	O
485	485	CD	O
and	and	CC	O
520ânm	520ânm	CD	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

Sprague	Sprague	NNP	O
-	-	HYPH	O
Dawley	Dawley	NNP	O
female	female	JJ	O
rats	rat	NNS	O
seven	seven	CD	O
weeks	week	NNS	O
old	old	JJ	O
were	be	VBD	O
purchased	purchase	VBN	O
from	from	IN	O
Orient	Orient	NNP	O
Bio	Bio	NNP	O
Inc	Inc	NNP	O
Gyeonggi	Gyeonggi	NNP	O
,	,	,	O
South	South	NNP	O
Korea	Korea	NNP	O
and	and	CC	O
were	be	VBD	O
acclimatised	acclimatise	VBN	O
to	to	IN	O
the	the	DT	O
lab	lab	NN	O
condition	condition	NN	O
for	for	IN	O
1âweek	1âweek	CD	O
by	by	IN	O
giving	give	VBG	O
food	food	NN	O
and	and	CC	O
water	water	NN	O
provided	provide	VBD	O
ad	ad	NN	O
libitum	libitum	NN	O
.	.	.	O

Rats	rat	NNS	O
were	be	VBD	O
fasted	fast	VBN	O
for	for	IN	O
24âh	24âh	CD	O
before	before	IN	O
TNBS	TNBS	NNP	O
injection	injection	NN	O
0.8âml	0.8âml	CD	O
of	of	IN	O
5	5	CD	O
%	%	NN	O
TNBS	TNBS	NNP	O
in	in	IN	O
50	50	CD	O
%	%	NN	O
ethanol	ethanol	NN	O
into	into	IN	O
the	the	DT	O
lumen	luman	NNS	O
of	of	IN	O
the	the	DT	O
colon	colon	NN	O
8âcm	8âcm	CD	O
proximal	proximal	JJ	O
to	to	IN	O
the	the	DT	O
anus	anus	NN	O
through	through	IN	O
the	the	DT	O
rectum	rectum	NN	O
through	through	IN	O
an	an	DT	O
polyethylene	polyethylene	NN	O
catheter	catheter	NN	O
fitted	fit	VBD	O
onto	onto	IN	O
a	a	DT	O
1âml	1âml	CD	O
syringe	syringe	NN	O
.	.	.	O

Right	right	RB	O
after	after	IN	O
TNBS	TNBS	NNP	O
injection	injection	NN	O
,	,	,	O
rats	rat	NNS	O
were	be	VBD	O
kept	keep	VBN	O
in	in	IN	O
vertical	vertical	JJ	O
position	position	NN	O
for	for	IN	O
1âmin	1âmin	CD	O
before	before	IN	O
being	be	VBG	O
returned	return	VBN	O
to	to	IN	O
the	the	DT	O
cage	cage	NN	O
.	.	.	O

Next	next	JJ	O
day	day	NN	O
,	,	,	O
sulfasalazine	sulfasalazine	NN	O
300âmg	300âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
or	or	CC	O
compounds	compound	NNS	O
1âmg	1âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
in	in	IN	O
corn	corn	NN	O
oil	oil	NN	O
was	be	VBD	O
administered	administer	VBN	O
for	for	IN	O
up	up	IN	O
to	to	IN	O
5âdays	5âdays	CD	O
.	.	.	O

The	the	DT	O
doses	dose	NNS	O
of	of	IN	O
the	the	DT	O
drug	drug	NN	O
were	be	VBD	O
selected	select	VBN	O
based	base	VBN	O
on	on	IN	O
the	the	DT	O
previous	previous	JJ	O
studies	study	NNS	B
,	,	,	B
.	.	.	O

On	on	IN	O
the	the	DT	O
sixth	sixth	JJ	O
day	day	NN	O
,	,	,	O
all	all	PDT	O
the	the	DT	O
rats	rat	NNS	O
were	be	VBD	O
sacrificed	sacrifice	VBN	O
and	and	CC	O
macroscopic	macroscopic	JJ	O
observations	observation	NNS	O
were	be	VBD	O
evaluated	evaluate	VBN	O
for	for	IN	O
ulceration	ulceration	NN	O
and	and	CC	O
severity	severity	NN	O
of	of	IN	O
colitis	colitis	NN	O
.	.	.	O

The	the	DT	O
colon	colon	NN	O
tissues	tissue	VBZ	O
from	from	IN	O
5	5	CD	O
to	to	IN	O
7âcm	7âcm	CD	O
proximal	proximal	JJ	O
to	to	IN	O
rectum	rectum	NN	O
were	be	VBD	O
excised	excise	VBN	O
.	.	.	O

The	the	DT	O
colon	colon	NN	O
tissues	tissue	NNS	O
were	be	VBD	O
stored	store	VBN	O
at	at	IN	O
â80âÂ	â80âÂ	NNS	O
°	°	NNS	O
C	C	NNP	O
to	to	TO	O
examine	examine	VB	O
the	the	DT	O
protein	protein	NN	O
expression	expression	NN	O
of	of	IN	O
inflammatory	inflammatory	JJ	O
mediators	mediator	NNS	O
,	,	,	O
junctional	junctional	NNP	O
molecules	molecule	NNS	O
,	,	,	O
and	and	CC	O
transcription	transcription	NN	O
factors	factor	NNS	O
.	.	.	O

The	the	DT	O
study	study	NN	O
protocol	protocol	NN	O
of	of	IN	O
the	the	DT	O
animal	animal	NN	O
experiment	experiment	NN	O
was	be	VBD	O
reviewed	review	VBN	O
and	and	CC	O
approved	approve	VBN	O
beforehand	beforehand	RB	O
by	by	IN	O
the	the	DT	O
Institutional	Institutional	NNP	O
Animal	Animal	NNP	O
Care	Care	NNP	O
and	and	CC	O
Use	Use	NNP	O
Committee	Committee	NNP	O
of	of	IN	O
Yeungnam	Yeungnam	NNP	O
University	University	NNP	O
and	and	CC	O
were	be	VBD	O
performed	perform	VBN	O
following	follow	VBG	O
the	the	DT	O
institutional	institutional	JJ	O
guidelines	guideline	NNS	O
of	of	IN	O
the	the	DT	O
Institute	Institute	NNP	O
of	of	IN	O
Laboratory	Laboratory	NNP	O
Animal	Animal	NNP	O
Resources	Resources	NNPS	O
1996	1996	CD	O
,	,	,	O
and	and	CC	O
of	of	IN	O
Yeungnam	Yeungnam	NNP	O
University	University	NNP	O
for	for	IN	O
the	the	DT	O
care	care	NN	O
and	and	CC	O
use	use	NN	O
of	of	IN	O
animals	animal	NNS	O
2009	2009	CD	O
.	.	.	O

Colon	colon	NN	O
myeloperoxidase	myeloperoxidase	NN	O
MPO	MPO	NNP	O
level	level	NN	O
was	be	VBD	O
measured	measure	VBN	O
by	by	IN	O
using	use	VBG	O
MPO	MPO	NNP	O
Rat	Rat	NNP	O
ELISA	ELISA	NNP	O
kit	kit	NN	O
HK105	HK105	NNP	O
-	-	HYPH	O
01	01	CD	O
,	,	,	O
Hycult	hycult	NN	O
biotechnology	biotechnology	NN	O
,	,	,	O
Netherland	Netherland	NNP	O
.	.	.	O

Colon	colon	NN	O
tissues	tissue	NNS	O
were	be	VBD	O
weighed	weigh	VBN	O
,	,	,	O
washed	wash	VBN	O
in	in	IN	O
cold	cold	JJ	O
1Ã	1ã	CD	O
PBS	PBS	NNP	O
pH	pH	NNP	O
:	:	:	O
7.4	7.4	CD	O
,	,	,	O
and	and	CC	O
homogenised	homogenise	VBN	O
in	in	IN	O
500âÎ¼L	500âî¼l	CD	O
of	of	IN	O
ice	ice	NN	O
-	-	HYPH	O
cold	cold	JJ	O
lysis	lysis	NN	O
buffer	buffer	NN	O
pH	pH	NNP	O
7.4	7.4	CD	O
,	,	,	O
200âmM	200âmm	CD	O
NaCl	NaCl	NNP	O
,	,	,	O
5âmM	5âmm	CD	O
EDTA	edta	NN	O
,	,	,	O
10âmM	10âmm	CD	O
Tris	Tris	NNP	O
,	,	,	O
10	10	CD	O
%	%	NN	O
glycerol	glycerol	NN	O
,	,	,	O
1âmM	1âmm	CD	O
PMSF	PMSF	NNP	O
,	,	,	O
1âÂµg	1âÂµg	NNP	O
/	/	SYM	O
mL	mL	NNP	O
leupeptide	leupeptide	VBP	O
,	,	,	O
28âÂµg	28ââµg	CD	O
/	/	SYM	O
mL	mL	NNP	O
aprotinin	aprotinin	NN	O
by	by	IN	O
using	use	VBG	O
a	a	DT	O
Bead	Bead	NNP	O
Blaster	Blaster	NNP	O
Benchmark	benchmark	JJ	O
scientific	scientific	JJ	O
,	,	,	O
Edison	Edison	NNP	O
,	,	,	O
NJ	NJ	NNP	O
,	,	,	O
USA	USA	NNP	O
.	.	.	O

MPO	MPO	NNP	O
amount	amount	NN	O
in	in	IN	O
the	the	DT	O
supernatant	supernatant	NN	O
was	be	VBD	O
measured	measure	VBN	O
by	by	IN	O
detecting	detect	VBG	O
the	the	DT	O
absorbance	absorbance	NN	O
at	at	IN	O
450ânm	450ânm	CD	O
in	in	IN	O
microplate	microplate	NN	O
reader	reader	NN	O
Spectrostar	Spectrostar	NNP	O
Nano	Nano	NNP	O
,	,	,	O
BMG	BMG	NNP	O
LABTECH	LABTECH	NNP	O
,	,	,	O
Ortenberg	Ortenberg	NNP	O
,	,	,	O
Germany	Germany	NNP	O
.	.	.	O

Total	total	JJ	O
protein	protein	NN	O
from	from	IN	O
the	the	DT	O
colon	colon	NN	O
was	be	VBD	O
extracted	extract	VBN	O
by	by	IN	O
using	use	VBG	O
radioimmunoprecipitation	radioimmunoprecipitation	NN	O
assay	assay	NNP	O
RIPA	RIPA	NNP	O
buffer	buffer	NN	O
150âmM	150âmm	CD	O
Sodium	Sodium	NNP	O
chloride	chloride	NN	O
,	,	,	O
1	1	CD	O
%	%	NN	O
Triton	Triton	NNP	O
X-100	X-100	NNP	O
,	,	,	O
0.5	0.5	CD	O
%	%	NN	O
Sodium	Sodium	NNP	O
deoxycholate	deoxycholate	NN	O
,	,	,	O
0.1	0.1	CD	O
%	%	NN	O
SDS	sds	NN	O
and	and	CC	O
50âmM	50âmm	CD	O
Tris	Tris	NNP	O
adjusted	adjust	VBN	O
to	to	IN	O
pH	pH	NNP	O
8.0	8.0	CD	O
containing	contain	VBG	O
1X	1x	NN	O
proteases	protease	NNS	O
and	and	CC	O
phosphatase	phosphatase	NN	O
inhibitor	inhibitor	NN	O
Thermo	Thermo	NNP	O
Scientific	Scientific	NNP	O
,	,	,	O
Rockford	Rockford	NNP	O
,	,	,	O
USA	USA	NNP	O
.	.	.	O

Cytosolic	cytosolic	JJ	O
and	and	CC	O
nuclear	nuclear	JJ	O
proteins	protein	NNS	O
were	be	VBD	O
extracted	extract	VBN	O
by	by	IN	O
using	use	VBG	O
manufacturerâs	manufacturerâs	NNP	O
instruction	instruction	NN	O
given	give	VBN	O
by	by	IN	O
NE	NE	NNP	O
-	-	HYPH	O
PER	PER	NNP	O
nuclear	nuclear	JJ	O
and	and	CC	O
cytoplasmic	cytoplasmic	JJ	O
extraction	extraction	NN	O
reagent	reagent	NN	O
kit	kit	NNP	O
#	#	$	O
78833	78833	CD	O
,	,	,	O
Thermo	Thermo	NNP	O
Scientific	Scientific	NNP	O
,	,	,	O
Rockford	Rockford	NNP	O
,	,	,	O
USA	USA	NNP	O
.	.	.	O

Protein	protein	NN	O
concentrations	concentration	NNS	O
were	be	VBD	O
measured	measure	VBN	O
using	use	VBG	O
a	a	DT	O
BCA	BCA	NNP	O
protein	protein	NN	O
assay	assay	NN	O
kit	kit	NN	O
Pierce	Pierce	NNP	O
,	,	,	O
Rockford	Rockford	NNP	O
,	,	,	O
IL	IL	NNP	O
,	,	,	O
USA	USA	NNP	O
.	.	.	O

Equal	equal	JJ	O
amounts	amount	NNS	O
of	of	IN	O
total	total	JJ	O
proteins	protein	NNS	O
were	be	VBD	O
then	then	RB	O
separated	separate	VBN	O
by	by	IN	O
SDS	SDS	NNP	O
-	-	HYPH	O
PAGE	PAGE	NNP	O
and	and	CC	O
transferred	transfer	VBN	O
onto	onto	IN	O
Hybond	Hybond	NNP	O
ECL	ECL	NNP	O
nitrocellulose	nitrocellulose	NN	O
membranes	membrane	NNS	O
Amersham	Amersham	NNP	O
Life	Life	NNP	O
Science	Science	NNP	O
,	,	,	O
Buckinghamshire	Buckinghamshire	NNP	O
,	,	,	O
UK	UK	NNP	O
at	at	IN	O
200âmA	200âma	CD	O
for	for	IN	O
1âh	1âh	CD	O
.	.	.	O

Blocking	block	VBG	O
was	be	VBD	O
done	do	VBN	O
using	use	VBG	O
5	5	CD	O
%	%	NN	O
BSA	BSA	NNP	O
in	in	IN	O
Tris	Tris	NNP	O
-	-	HYPH	O
buffered	buffer	VBN	O
saline	saline	NN	O
TBS)-Tween	tbs)-tween	CD	O
20	20	CD	O
TBS	TBS	NNP	O
-	-	HYPH	O
T	T	NNP	O
at	at	IN	O
20âÂ	20ââ	CD	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
1âh	1âh	CD	O
.	.	.	O

The	the	DT	O
membranes	membrane	NNS	O
were	be	VBD	O
incubated	incubate	VBN	O
for	for	IN	O
16âh	16âh	CD	O
at	at	IN	O
4âÂ	4ââ	CD	O
°	°	,	O
C	C	NNP	O
with	with	IN	O
primary	primary	JJ	O
antibody	antibody	NN	O
diluted	dilute	VBN	O
in	in	IN	O
TBS	TBS	NNP	O
containing	contain	VBG	O
3	3	CD	O
%	%	NN	O
BSA	BSA	NNP	O
.	.	.	O

After	after	IN	O
incubation	incubation	NN	O
,	,	,	O
the	the	DT	O
membranes	membrane	NNS	O
were	be	VBD	O
washed	wash	VBN	O
three	three	CD	O
times	time	NNS	O
with	with	IN	O
TBS	TBS	NNP	O
-	-	HYPH	O
T.	T.	NNP	O
Next	Next	NNP	O
,	,	,	O
the	the	DT	O
membrane	membrane	NN	O
was	be	VBD	O
incubated	incubate	VBN	O
for	for	IN	O
1âh	1âh	CD	O
at	at	IN	O
20âÂ	20ââ	CD	O
°	°	,	O
C	C	NNP	O
with	with	IN	O
horseradish	horseradish	NNP	O
peroxidase	peroxidase	NN	O
-	-	HYPH	O
conjugated	conjugate	VBN	O
secondary	secondary	JJ	O
antibody	antibody	NN	O
in	in	IN	O
TBS	TBS	NNP	O
.	.	.	O

Immunoreactive	immunoreactive	JJ	O
proteins	protein	NNS	O
were	be	VBD	O
visualised	visualise	VBN	O
using	use	VBG	O
an	an	DT	O
enhanced	enhanced	JJ	O
chemiluminescence	chemiluminescence	NN	O
ECL	ECL	NNP	O
kit	kit	NN	O
Pierce	Pierce	NNP	O
,	,	,	O
Rockford	Rockford	NNP	O
,	,	,	O
IL	IL	NNP	O
,	,	,	O
USA	USA	NNP	O
and	and	CC	O
digitally	digitally	RB	O
processed	process	VBN	O
using	use	VBG	O
an	an	DT	O
LAS-4000	LAS-4000	NNP	O
mini	mini	NN	O
Fuji	Fuji	NNP	O
,	,	,	O
Japan	Japan	NNP	O
.	.	.	O

The	the	DT	O
membranes	membrane	NNS	O
were	be	VBD	O
stripped	strip	VBN	O
and	and	CC	O
re	re	VBN	O
-	-	VBN	O
probed	probe	VBN	O
with	with	IN	O
an	an	DT	O
actin	actin	JJ	O
antibody	antibody	NN	O
as	as	IN	O
a	a	DT	O
loading	loading	NN	O
control	control	NN	O
.	.	.	O

Data	datum	NNS	O
are	be	VBP	O
presented	present	VBN	O
as	as	IN	O
the	the	DT	O
meanâÂ±âSEM	meanâÂ±âSEM	NNP	O
,	,	,	O
and	and	CC	O
were	be	VBD	O
analysed	analyse	VBN	O
by	by	IN	O
one	one	CD	O
way	way	NN	O
ANOVA	ANOVA	NNP	O
followed	follow	VBN	O
by	by	IN	O
the	the	DT	O
NewmanâKeuls	NewmanâKeuls	NNP	O
comparison	comparison	NN	O
method	method	NN	O
using	use	VBG	O
GraphPad	GraphPad	NNP	O
Prism	Prism	NNP	O
software	software	NN	O
version	version	NN	O
5.0	5.0	CD	O
,	,	,	O
San	San	NNP	O
Diego	Diego	NNP	O
,	,	,	O
CA	CA	NNP	O
,	,	,	O
USA	USA	NNP	O
.	.	.	O

P	p	NN	O
values	value	NNS	O
less	less	JJR	O
than	than	IN	O
0.05	0.05	CD	O
were	be	VBD	O
considered	consider	VBN	O
statistically	statistically	RB	O
significant	significant	JJ	O
.	.	.	O

At	at	IN	O
first	first	RB	O
,	,	,	O
we	-PRON-	PRP	O
were	be	VBD	O
curious	curious	JJ	O
about	about	IN	O
the	the	DT	O
effect	effect	NN	O
of	of	IN	O
heteroatom	heteroatom	NN	O
at	at	IN	O
C(6)-position	c(6)-position	NN	O
on	on	IN	O
activity	activity	NN	O
and	and	CC	O
replaced	replace	VBD	O
nitrogen	nitrogen	NN	O
with	with	IN	O
oxygen	oxygen	NN	O
to	to	TO	O
give	give	VB	O
6-alkoxy	6-alkoxy	CD	O
analogues	analogue	NNS	O
8	8	CD	O
.	.	.	O

Synthesis	Synthesis	NNP	O
of	of	IN	O
8	8	CD	O
was	be	VBD	O
conducted	conduct	VBN	O
via	via	IN	O
intermediate	intermediate	JJ	O
5	5	CD	O
which	which	WDT	O
has	have	VBZ	O
been	be	VBN	O
reported	report	VBN	O
by	by	IN	O
us	-PRON-	PRP	O
Scheme	Scheme	NNP	O
1	1	CD	O
)	)	-RRB-	B
.	.	.	O

Briefly	briefly	RB	O
,	,	,	O
two	two	CD	O
primary	primary	JJ	O
hydroxy	hydroxy	NN	O
groups	group	NNS	O
of	of	IN	O
pyridoxineÂ·HCl	pyridoxineÂ·HCl	NNP	O
1	1	CD	O
was	be	VBD	O
converted	convert	VBN	O
to	to	IN	O
chlorides	chloride	NNS	O
using	use	VBG	O
SOCl2	socl2	NN	O
and	and	CC	O
catalytic	catalytic	JJ	O
amount	amount	NN	O
of	of	IN	O
DMF	DMF	NNP	O
.	.	.	O

Then	then	RB	O
,	,	,	O
two	two	CD	O
benzyl	benzyl	NN	O
chloride	chloride	NN	O
groups	group	NNS	O
were	be	VBD	O
reductively	reductively	RB	O
removed	remove	VBN	O
with	with	IN	O
Zn	Zn	NNP	O
and	and	CC	O
acetic	acetic	JJ	O
acid	acid	NN	O
under	under	IN	O
refluxing	refluxe	VBG	O
conditions	condition	NNS	O
to	to	TO	O
give	give	VB	O
2,4,5-trimethylpyridin-3-ol	2,4,5-trimethylpyridin-3-ol	CD	O
2	2	CD	O
.	.	.	O

The	the	DT	O
C(6)-position	c(6)-position	NN	O
was	be	VBD	O
brominated	brominate	VBN	O
using	use	VBG	O
1,3-dibromo-5,5-dimethylhydantoin	1,3-dibromo-5,5-dimethylhydantoin	CD	O
DBDMH	dbdmh	NN	O
and	and	CC	O
the	the	DT	O
phenolic	phenolic	NN	O
OH	OH	NNP	O
group	group	NN	O
of	of	IN	O
3	3	CD	O
was	be	VBD	O
protected	protect	VBN	O
as	as	IN	O
benzyloxy	benzyloxy	JJ	O
group	group	NN	O
.	.	.	O

Bromide	bromide	NN	O
on	on	IN	O
C(6)-position	c(6)-position	NN	O
was	be	VBD	O
replaced	replace	VBN	O
with	with	IN	O
benzophenone	benzophenone	JJ	O
imine	imine	NN	O
under	under	IN	O
BuchwaldâHartwig	BuchwaldâHartwig	NNP	O
amination	amination	NN	O
conditions	condition	NNS	O
to	to	TO	O
afford	afford	VB	O
4	4	CD	O
.	.	.	O

The	the	DT	O
imine	imine	NN	O
group	group	NN	O
was	be	VBD	O
then	then	RB	O
methanolyzed	methanolyze	VBN	O
to	to	TO	O
give	give	VB	O
the	the	DT	O
free	free	JJ	O
amino	amino	NN	O
compound	compound	NNP	O
5	5	CD	O
.	.	.	O

The	the	DT	O
amino	amino	JJ	O
group	group	NN	O
of	of	IN	O
5	5	CD	O
was	be	VBD	O
converted	convert	VBN	O
to	to	IN	O
hydroxy	hydroxy	NNP	O
group	group	NN	O
via	via	IN	O
diazonium	diazonium	NN	O
ion	ion	NN	O
to	to	TO	O
give	give	VB	O
6	6	CD	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
then	then	RB	O
treated	treat	VBN	O
with	with	IN	O
various	various	JJ	O
alkyl	alkyl	NN	O
halides	halide	NNS	O
to	to	TO	O
give	give	VB	O
alkoxy	alkoxy	JJ	O
compounds	compound	NNS	O
7	7	CD	O
.	.	.	O

Lastly	lastly	RB	O
,	,	,	O
the	the	DT	O
benzyl	benzyl	NNP	O
protective	protective	JJ	O
group	group	NN	O
was	be	VBD	O
removed	remove	VBN	O
by	by	IN	O
catalytic	catalytic	JJ	O
hydrogenolysis	hydrogenolysis	NN	O
to	to	TO	O
give	give	VB	O
6-alkoxy-2,4,5-trimethylpyridin-3-ol	6-alkoxy-2,4,5-trimethylpyridin-3-ol	CD	O
analogues	analogue	NNS	O
8	8	CD	O
.	.	.	O

The	the	DT	O
dihydroxy	dihydroxy	NN	O
compound	compound	NN	O
8a	8a	NNP	O
was	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
the	the	DT	O
dibenzyloxy	dibenzyloxy	JJ	O
compound	compound	NN	O
7a	7a	NN	O
.	.	.	O

A	a	DT	O
direct	direct	JJ	O
approach	approach	NN	O
to	to	TO	O
obtain	obtain	VB	O
8a	8a	NNP	O
from	from	IN	O
6	6	CD	O
under	under	IN	O
the	the	DT	O
standard	standard	JJ	O
catalytic	catalytic	JJ	O
hydrogenolysis	hydrogenolysis	NN	O
reaction	reaction	NN	O
conditions	condition	NNS	O
gave	give	VBD	O
poor	poor	JJ	O
yield	yield	NN	O
.	.	.	O

Synthesis	synthesis	NN	O
of	of	IN	O
alkoxy	alkoxy	NN	O
-	-	HYPH	O
analogues	analogue	NNS	O
8	8	CD	O
.	.	.	O

Unfortunately	unfortunately	RB	O
,	,	,	O
all	all	DT	O
alkoxy	alkoxy	JJ	O
analogues	analogue	NNS	O
8aâ8f	8aâ8f	NFP	O
showed	show	VBD	O
modest	modest	JJ	O
activity	activity	NN	O
29â67	29â67	CD	O
%	%	NN	O
in	in	IN	O
our	-PRON-	PRP$	O
cell	cell	NN	O
adhesion	adhesion	NN	O
assay	assay	NN	O
Figure	figure	NN	O
2	2	CD	O
.	.	.	O

Compound	Compound	NNP	O
8a	8a	NNP	O
67	67	CD	O
%	%	NN	O
inhibition	inhibition	NN	O
and	and	CC	O
8f	8f	NN	O
56	56	CD	O
%	%	NN	O
inhibition	inhibition	NN	O
showed	show	VBD	O
2.9-	2.9-	CD	O
and	and	CC	O
2.1-fold	2.1-fold	CD	O
higher	high	JJR	O
activity	activity	NN	O
than	than	IN	O
the	the	DT	O
corresponding	corresponding	JJ	O
nitrogen	nitrogen	NN	O
counterparts	counterpart	NNS	O
whose	whose	WP$	O
inhibition	inhibition	NN	O
level	level	NN	O
was	be	VBD	O
23	23	CD	O
%	%	NN	O
and	and	CC	O
27	27	CD	O
%	%	NN	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

Contrarily	contrarily	RB	O
,	,	,	O
compound	compound	NN	O
8e	8e	CD	O
29	29	CD	O
%	%	NN	O
inhibition	inhibition	NN	O
showed	show	VBD	O
2.5-fold	2.5-fold	CD	O
less	less	JJR	O
activity	activity	NN	O
than	than	IN	O
the	the	DT	O
corresponding	corresponding	JJ	O
nitrogen	nitrogen	NN	O
counterpart	counterpart	NN	O
73	73	CD	O
%	%	NN	O
inhibition	inhibition	NN	O
)	)	-RRB-	B
.	.	.	O

The	the	DT	O
rest	rest	NN	O
of	of	IN	O
alkoxy	alkoxy	JJ	O
analogues	analogue	NNS	O
with	with	IN	O
alkyl	alkyl	JJ	O
groups	group	NNS	O
8âb	8âb	NNP	O
,	,	,	O
8c	8c	CD	O
,	,	,	O
8d	8d	NNP	O
did	do	VBD	O
not	not	RB	O
show	show	VB	O
distinct	distinct	JJ	O
activity	activity	NN	O
from	from	IN	O
6-alkylamino	6-alkylamino	CD	O
analogues	analogue	NNS	O
.	.	.	O

It	-PRON-	PRP	O
seems	seem	VBZ	O
that	that	IN	O
nitrogen	nitrogen	NN	O
atom	atom	NN	O
does	do	VBZ	O
not	not	RB	O
necessarily	necessarily	RB	O
be	be	VB	O
replaced	replace	VBN	O
and	and	CC	O
might	may	MD	O
be	be	VB	O
better	well	JJR	O
to	to	TO	O
remain	remain	VB	O
on	on	IN	O
C(6)-position	c(6)-position	NN	O
for	for	IN	O
the	the	DT	O
better	well	JJR	O
topological	topological	JJ	O
polar	polar	JJ	O
surface	surface	NN	O
area	area	NN	O
tPSA	tpsa	NN	O
and	and	CC	O
calculated	calculate	VBN	O
partition	partition	NN	O
coefficient	coefficient	NN	O
cLogP	clogp	NN	O
.	.	.	O

By	by	IN	O
locating	locate	VBG	O
nitrogen	nitrogen	NN	O
back	back	RB	O
to	to	IN	O
C(6)-position	c(6)-position	NN	O
,	,	,	O
about	about	RB	O
10	10	CD	O
%	%	NN	O
of	of	IN	O
both	both	DT	O
tPSA	tpsa	NN	O
and	and	CC	O
cLogP	clogp	NN	O
values	value	NNS	O
can	can	MD	O
be	be	VB	O
restored	restore	VBN	O
compared	compare	VBN	O
to	to	IN	O
the	the	DT	O
alkoxy	alkoxy	JJ	O
analogues	analogue	NNS	O
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
we	-PRON-	PRP	O
decided	decide	VBD	O
to	to	TO	O
explore	explore	VB	O
structural	structural	JJ	O
diversity	diversity	NN	O
with	with	IN	O
nitrogen	nitrogen	NN	O
atom	atom	NN	O
on	on	IN	O
the	the	DT	O
position	position	NN	O
.	.	.	O

Inhibitory	inhibitory	NN	O
activity	activity	NN	O
of	of	IN	O
the	the	DT	O
compounds	compound	NNS	O
against	against	IN	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±-induced	î±-induce	VBN	O
monocyte	monocyte	NN	O
adhesion	adhesion	NN	O
to	to	TO	O
colon	colon	VB	O
epithelial	epithelial	JJ	O
cells	cell	NNS	O
.	.	.	O

Data	datum	NNS	O
are	be	VBP	O
shown	show	VBN	O
as	as	IN	O
meanâÂ±âSEM	meanâÂ±âSEM	NNP	O
of	of	IN	O
at	at	RB	O
least	least	RBS	O
three	three	CD	O
independent	independent	JJ	O
experiments	experiment	NNS	O
.	.	.	O

*	*	NFP	O
pâ<â0.05	pâ<â0.05	NNP	O
compared	compare	VBN	O
to	to	IN	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±-induced	Î±-induced	NNP	O
HT-29	HT-29	NNP	O
cells	cell	NNS	O
.	.	.	O

Now	now	RB	O
that	that	IN	O
we	-PRON-	PRP	O
have	have	VBP	O
reported	report	VBN	O
that	that	IN	O
6-(substituted)amino-2,4,5-trimethylpyridin-3-ols	6-(substituted)amino-2,4,5-trimethylpyridin-3-ols	CD	O
have	have	VB	O
high	high	JJ	O
activity	activity	NN	O
against	against	IN	O
colitis	colitis	NN	O
in	in	IN	O
vitro	vitro	FW	O
and	and	CC	O
in	in	IN	O
vivo	vivo	NNP	O
,	,	,	O
structural	structural	JJ	O
exploration	exploration	NN	O
with	with	IN	O
nitrogen	nitrogen	NN	O
on	on	IN	O
C(6)-position	c(6)-position	NN	O
was	be	VBD	O
designed	design	VBN	O
to	to	TO	O
install	install	VB	O
ureido-	ureido-	NN	O
,	,	,	O
thioureido-	thioureido-	JJ	O
,	,	,	O
carbamato-	carbamato-	NNP	O
and	and	CC	O
sulfonamido	sulfonamido	NN	O
-	-	HYPH	O
linkage	linkage	NN	O
between	between	IN	O
pyridine	pyridine	JJ	O
ring	ring	NN	O
and	and	CC	O
R	r	NN	O
group	group	NN	O
.	.	.	O

Described	describe	VBN	O
in	in	IN	O
Scheme	Scheme	NNP	O
2	2	CD	O
is	be	VBZ	O
the	the	DT	O
general	general	JJ	O
scheme	scheme	NN	O
for	for	IN	O
the	the	DT	O
preparation	preparation	NN	O
of	of	IN	O
urea	urea	NNP	O
and	and	CC	O
thiourea	thiourea	NNP	O
analogues	analogues	NNP	O
,	,	,	O
13	13	CD	O
and	and	CC	O
14	14	CD	O
.	.	.	O

Isocyanates	isocyanate	NNS	O
RâââNâ=âCâ=âO)/isothiocyanates	rââânâ=âcâ=âo)/isothiocyanate	NNS	O
RâââNâ=âCâ=âS	RâââNâ=âCâ=âS	NNP	O
were	be	VBD	O
employed	employ	VBN	O
for	for	IN	O
the	the	DT	O
construction	construction	NN	O
of	of	IN	O
urea	urea	NNP	O
/	/	SYM	O
thiourea	thiourea	NNP	O
moieties	moiety	NNS	O
.	.	.	O

Two	two	CD	O
key	key	JJ	O
intermediates	intermediate	NNS	O
,	,	,	O
5	5	CD	O
and	and	CC	O
10	10	CD	O
,	,	,	O
were	be	VBD	O
used	use	VBN	O
for	for	IN	O
the	the	DT	O
coupling	couple	VBG	O
reactions	reaction	NNS	O
and	and	CC	O
the	the	DT	O
TBDPS	TBDPS	NNP	O
-	-	HYPH	O
protected	protect	VBN	O
intermediate	intermediate	NN	O
10	10	CD	O
was	be	VBD	O
prepared	prepare	VBN	O
by	by	IN	O
the	the	DT	O
synthetic	synthetic	JJ	O
procedure	procedure	NN	O
which	which	WDT	O
we	-PRON-	PRP	O
reported	report	VBD	O
before	before	IN	B
.	.	.	O

In	in	IN	O
short	short	JJ	O
,	,	,	O
compound	compound	NNP	O
10	10	CD	O
was	be	VBD	O
prepared	prepare	VBN	O
from	from	IN	O
2,4,5-trimethylpyridin-3-ol	2,4,5-trimethylpyridin-3-ol	CD	O
2	2	CD	O
by	by	IN	O
the	the	DT	O
following	follow	VBG	O
sequence	sequence	NN	O
;	;	:	O
bromination	bromination	NN	O
of	of	IN	O
C(6)-position	c(6)-position	NN	O
,	,	,	O
protection	protection	NN	O
ofâââOH	ofâââoh	NN	O
with	with	IN	O
TBDPS	TBDPS	NNP	O
group	group	NN	O
,	,	,	O
palladium	palladium	NN	O
-	-	HYPH	O
catalyzed	catalyzed	JJ	O
amination	amination	NN	O
with	with	IN	O
benzophenone	benzophenone	JJ	O
imine	imine	NN	O
,	,	,	O
and	and	CC	O
acidic	acidic	JJ	O
methanolysis	methanolysis	NN	O
of	of	IN	O
the	the	DT	O
imine	imine	NN	O
group	group	NN	O
.	.	.	O

The	the	DT	O
coupled	couple	VBN	O
products	product	NNS	O
with	with	IN	O
isocyanates	isocyanate	NNS	O
and	and	CC	O
isothiocyanates	isothiocyanate	NNS	O
,	,	,	O
11	11	CD	O
and	and	CC	O
12	12	CD	O
,	,	,	O
were	be	VBD	O
then	then	RB	O
transformed	transform	VBN	O
the	the	DT	O
final	final	JJ	O
compounds	compound	NNS	O
,	,	,	O
13	13	CD	O
and	and	CC	O
14	14	CD	O
,	,	,	O
by	by	IN	O
deprotection	deprotection	NN	O
of	of	IN	O
O	o	NN	O
-	-	HYPH	O
benzyl	benzyl	NNP	O
or	or	CC	O
O	O	NNP	O
-	-	HYPH	O
silyl	silyl	NNP	O
group	group	NN	O
.	.	.	O

For	for	IN	O
14a	14a	CD	O
compound	compound	NNP	O
withâââNH2	withâââNH2	NNP	O
group	group	NN	O
,	,	,	O
the	the	DT	O
precursor	precursor	NN	O
,	,	,	O
O	O	NNP	O
-	-	HYPH	O
benzyl	benzyl	NNP	O
protected	protect	VBD	O
compound	compound	NN	O
12a	12a	NNS	O
,	,	,	O
was	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
N	N	NNP	O
-	-	HYPH	O
benzoyl	benzoyl	NNP	O
thiourea	thiourea	NNP	O
compound	compound	NNP	O
12n	12n	NNS	O
by	by	IN	O
a	a	DT	O
debenzoylation	debenzoylation	NN	O
under	under	IN	O
basic	basic	JJ	O
hydrolysis	hydrolysis	NN	O
conditions	condition	NNS	O
.	.	.	O

Synthesis	synthesis	NN	O
of	of	IN	O
ureido-	ureido-	NN	O
and	and	CC	O
thioureido	thioureido	NN	O
-	-	HYPH	O
analogues	analogue	NNS	O
,	,	,	O
13	13	CD	O
and	and	CC	O
14	14	CD	O
.	.	.	O

For	for	IN	O
the	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
sulfonamido-	sulfonamido-	NN	O
16	16	CD	O
and	and	CC	O
carbamato	carbamato	NNP	O
-	-	HYPH	O
analogues	analogues	NNP	O
18	18	CD	O
,	,	,	O
the	the	DT	O
key	key	NN	O
intermediate	intermediate	NNP	O
5	5	CD	O
was	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
either	either	DT	O
chloroformates	chloroformate	NNS	O
or	or	CC	O
sulphonyl	sulphonyl	NN	O
chlorides	chloride	NNS	O
to	to	TO	O
give	give	VB	O
15	15	CD	O
and	and	CC	O
17	17	CD	O
.	.	.	O

They	-PRON-	PRP	O
were	be	VBD	O
then	then	RB	O
debenzylated	debenzylate	VBN	O
to	to	TO	O
afford	afford	VB	O
16	16	CD	O
and	and	CC	O
18	18	CD	O
,	,	,	O
respectively	respectively	RB	O
Scheme	Scheme	NNP	O
3	3	CD	O
.	.	.	O

Synthesis	synthesis	NN	O
of	of	IN	O
carbamato-	carbamato-	NNS	O
and	and	CC	O
sulfonamido-	sulfonamido-	NNP	O
analogues	analogue	NNS	O
,	,	,	O
16	16	CD	O
and	and	CC	O
18	18	CD	O
.	.	.	O

In	in	IN	O
vitro	vitro	FW	O
activity	activity	NN	O
data	datum	NNS	O
of	of	IN	O
the	the	DT	O
alkoxy-	alkoxy-	NN	O
8)	8)	CD	O
,	,	,	O
ureido-	ureido-	JJ	O
13	13	CD	O
,	,	,	O
thioureido-	thioureido-	JJ	O
14	14	CD	O
,	,	,	O
carbamato-	carbamato-	NNP	O
16	16	CD	O
and	and	CC	O
sulfonamido	sulfonamido	NN	O
-	-	HYPH	O
analogues	analogue	NNS	O
18	18	CD	O
are	be	VBP	O
listed	list	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
2	2	CD	O
.	.	.	O

As	as	IN	O
stated	state	VBN	O
above	above	IN	O
,	,	,	O
alkoxy	alkoxy	JJ	O
analogues	analogue	NNS	O
8)	8)	CD	O
showed	show	VBD	O
activity	activity	NN	O
in	in	IN	O
a	a	DT	O
somewhat	somewhat	RB	O
similar	similar	JJ	O
range	range	NN	O
to	to	IN	O
the	the	DT	O
nitrogen	nitrogen	NN	O
counterparts	counterpart	NNS	O
.	.	.	O

The	the	DT	O
best	good	JJS	O
activity	activity	NN	O
67	67	CD	O
%	%	NN	O
was	be	VBD	O
seen	see	VBN	O
in	in	IN	O
compound	compound	NNP	O
8a	8a	NNS	O
which	which	WDT	O
has	have	VBZ	O
no	no	DT	O
substituent	substituent	NN	O
on	on	IN	O
C(6)-oxygen	c(6)-oxygen	NN	O
.	.	.	O

Activity	Activity	NNP	O
of	of	IN	O
urea	urea	NNP	O
13	13	CD	O
and	and	CC	O
thiourea	thiourea	NNP	O
14	14	CD	O
analogues	analogue	NNS	O
are	be	VBP	O
also	also	RB	O
in	in	IN	O
a	a	DT	O
similar	similar	JJ	O
range	range	NN	O
.	.	.	O

Among	among	IN	O
the	the	DT	O
compounds	compound	NNS	O
with	with	IN	O
the	the	DT	O
same	same	JJ	O
R	r	NN	O
group	group	NN	O
,	,	,	O
the	the	DT	O
phenyl	phenyl	NNP	O
group	group	NN	O
is	be	VBZ	O
more	more	RBR	O
active	active	JJ	O
in	in	IN	O
urea	urea	NNP	O
analogue	analogue	NNP	O
13âb	13âb	CD	O
:	:	:	O
76.3	76.3	CD	O
%	%	NN	O
than	than	IN	O
in	in	IN	O
thiourea	thiourea	NNP	O
analogue	analogue	NNP	O
14e	14e	NNS	O
:	:	:	O
49.7	49.7	CD	O
%	%	NN	O
.	.	.	O

Both	both	DT	O
p	p	NN	O
-	-	HYPH	O
tolyl	tolyl	JJ	O
and	and	CC	O
p	p	NNP	O
-	-	HYPH	O
methoxyphenyl	methoxyphenyl	NN	O
groups	group	NNS	O
showed	show	VBD	O
similar	similar	JJ	O
and	and	CC	O
low	low	JJ	O
activity	activity	NN	O
both	both	CC	O
in	in	IN	O
urea	urea	NNP	O
analogues	analogue	NNS	O
13d	13d	CD	O
:	:	:	O
20.1	20.1	CD	O
%	%	NN	O
,	,	,	O
13j	13j	CD	O
:	:	:	O
12.6	12.6	CD	O
%	%	NN	O
,	,	,	O
respectively	respectively	RB	O
and	and	CC	O
thiourea	thiourea	NNP	O
analogues	analogue	NNS	O
14f	14f	NNS	O
:	:	:	O
19.2	19.2	CD	O
%	%	NN	O
,	,	,	O
14âg	14âg	CD	O
:	:	:	O
13.3	13.3	CD	O
%	%	NN	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

IC50	ic50	NN	O
values	value	NNS	O
of	of	IN	O
some	some	DT	O
compounds	compound	NNS	O
of	of	IN	O
high	high	JJ	O
%	%	NN	O
inhibition	inhibition	NN	O
were	be	VBD	O
measured	measure	VBN	O
to	to	TO	O
be	be	VB	O
0.75âÎ¼M	0.75âî¼m	NN	O
8f	8f	NNP	O
,	,	,	O
0.41âÎ¼M	0.41âî¼m	NN	O
13âb	13âb	CD	O
,	,	,	O
0.40âÎ¼M	0.40âî¼m	NN	O
14n	14n	NNS	O
,	,	,	O
0.32âÎ¼M	0.32âÎ¼M	NNP	O
18d	18d	SYM	O
,	,	,	O
and	and	CC	O
0.23âÎ¼M	0.23âî¼m	NN	O
18c	18c	CD	O
.	.	.	O

The	the	DT	O
order	order	NN	O
of	of	IN	O
these	these	DT	O
values	value	NNS	O
is	be	VBZ	O
quite	quite	RB	O
lined	line	VBN	O
with	with	IN	O
the	the	DT	O
order	order	NN	O
of	of	IN	O
%	%	NN	O
inhibition	inhibition	NN	O
measured	measure	VBN	O
at	at	IN	O
the	the	DT	O
fixed	fix	VBN	O
single	single	JJ	O
concentration	concentration	NN	O
1âÎ¼M	1âî¼m	CD	O
.	.	.	O

Next	next	RB	O
,	,	,	O
we	-PRON-	PRP	O
tried	try	VBD	O
to	to	TO	O
investigate	investigate	VB	O
the	the	DT	O
role	role	NN	O
âOH	âOH	NNP	O
group	group	NN	O
on	on	IN	O
C(3)-position	c(3)-position	NN	O
on	on	IN	O
the	the	DT	O
activity	activity	NN	O
.	.	.	O

The	the	DT	O
hydroxy	hydroxy	NN	O
group	group	NN	O
is	be	VBZ	O
protected	protect	VBN	O
as	as	IN	O
methoxy	methoxy	NN	O
group	group	NN	O
as	as	IN	O
shown	show	VBN	O
in	in	IN	O
structure	structure	NN	O
22	22	CD	O
to	to	TO	O
study	study	VB	O
if	if	IN	O
the	the	DT	O
OH	OH	NNP	O
group	group	NN	O
is	be	VBZ	O
essential	essential	JJ	O
Scheme	Scheme	NNP	O
4	4	CD	O
.	.	.	O

Compounds	compound	NNS	O
22a	22a	NNPS	O
and	and	CC	O
22âb	22âb	CD	O
are	be	VBP	O
3-methoxy	3-methoxy	CD	O
analogues	analogue	NNS	O
of	of	IN	O
14j	14j	NNS	O
and	and	CC	O
14k	14k	NNS	O
,	,	,	O
respectively	respectively	RB	O
,	,	,	O
which	which	WDT	O
showed	show	VBD	O
excellent	excellent	JJ	O
activity	activity	NN	O
in	in	IN	O
our	-PRON-	PRP$	O
in	in	FW	O
vitro	vitro	FW	O
assay	assay	NNP	O
as	as	IN	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
1	1	CD	O
.	.	.	O

The	the	DT	O
intermediate	intermediate	JJ	O
3	3	CD	O
is	be	VBZ	O
methylated	methylate	VBN	O
with	with	IN	O
iodomethane	iodomethane	NNP	O
and	and	CC	O
K2CO3	K2CO3	NNP	O
to	to	TO	O
give	give	VB	O
3-methoxy	3-methoxy	CD	O
compound	compound	NN	O
19	19	CD	O
.	.	.	O

Then	then	RB	O
,	,	,	O
benzophenone	benzophenone	JJ	O
imine	imine	NN	O
was	be	VBD	O
coupled	couple	VBN	O
under	under	IN	O
Buchwald	Buchwald	NNP	O
-	-	HYPH	O
Hartwig	Hartwig	NNP	O
amination	amination	NN	O
conditions	condition	NNS	O
to	to	TO	O
afford	afford	VB	O
imino	imino	JJ	O
compound	compound	NNP	O
20	20	CD	O
which	which	WDT	O
in	in	IN	O
turn	turn	NN	O
was	be	VBD	O
hydrolysed	hydrolyse	VBN	O
to	to	TO	O
free	free	VB	O
amino	amino	NN	O
compound	compound	NN	O
21	21	CD	O
.	.	.	O

The	the	DT	O
amino	amino	JJ	O
group	group	NN	O
of	of	IN	O
21	21	CD	O
was	be	VBD	O
coupled	couple	VBN	O
with	with	IN	O
isothiocyanates	isothiocyanate	NNS	O
to	to	TO	O
give	give	VB	O
22a	22a	NNS	O
and	and	CC	O
22âb	22âb	CD	O
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
2	2	CD	O
,	,	,	O
unfortunately	unfortunately	RB	O
,	,	,	O
3-methoxy	3-methoxy	CD	O
analogues	analogue	NNS	O
22a	22a	NNS	O
and	and	CC	O
22âb	22âb	CD	O
showed	show	VBD	O
more	more	JJR	O
than	than	IN	O
2-fold	2-fold	CD	O
less	less	JJR	O
activity	activity	NN	O
than	than	IN	O
corresponding	correspond	VBG	O
3-hydroxy	3-hydroxy	CD	O
analogues	analogue	NNS	O
,	,	,	O
14j	14j	NNS	O
and	and	CC	O
14k	14k	NNS	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

It	-PRON-	PRP	O
might	may	MD	O
imply	imply	VB	O
that	that	DT	O
free	free	JJ	O
hydroxyl	hydroxyl	NNP	O
group	group	NN	O
at	at	IN	O
3-position	3-position	CD	O
is	be	VBZ	O
essential	essential	JJ	O
to	to	IN	O
the	the	DT	O
activity	activity	NN	O
by	by	IN	O
contributing	contribute	VBG	O
some	some	DT	O
sort	sort	NN	O
of	of	IN	O
hydrogen	hydrogen	NN	O
bonding	bonding	NN	O
to	to	IN	O
a	a	DT	O
binding	bind	VBG	O
partner	partner	NN	O
which	which	WDT	O
is	be	VBZ	O
responsible	responsible	JJ	O
for	for	IN	O
the	the	DT	O
activity	activity	NN	O
.	.	.	O

Further	further	JJ	O
detail	detail	NN	O
of	of	IN	O
the	the	DT	O
role	role	NN	O
of	of	IN	O
hydroxyl	hydroxyl	NNP	O
group	group	NN	O
will	will	MD	O
be	be	VB	O
investigated	investigate	VBN	O
in	in	IN	O
subsequent	subsequent	JJ	O
studies	study	NNS	O
.	.	.	O

Synthesis	Synthesis	NNP	O
of	of	IN	O
3-methoxy	3-methoxy	CD	O
analogues	analogue	NNS	O
,	,	,	O
22	22	CD	O
.	.	.	O

Next	next	RB	O
,	,	,	O
we	-PRON-	PRP	O
evaluated	evaluate	VBD	O
in	in	IN	O
vivo	vivo	NNP	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activity	activity	NN	O
using	use	VBG	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
rat	rat	NN	O
colitis	colitis	NN	O
model	model	NN	O
.	.	.	O

Seven	seven	CD	O
pyridin-3-ol	pyridin-3-ol	NNP	O
compounds	compound	NNS	O
,	,	,	O
13âb	13âb	CD	O
,	,	,	O
14c	14c	NNS	O
,	,	,	O
14j	14j	NNS	O
,	,	,	O
14k	14k	NNS	O
,	,	,	O
14n	14n	NNS	O
,	,	,	O
18c	18c	NNS	O
,	,	,	O
and	and	CC	O
18d	18d	NNS	O
,	,	,	O
were	be	VBD	O
selected	select	VBN	O
for	for	IN	O
the	the	DT	O
in	in	IN	O
vivo	vivo	NNP	O
efficacy	efficacy	NN	O
evaluation	evaluation	NN	O
along	along	IN	O
with	with	IN	O
sulfasalazine	sulfasalazine	NN	O
SSZ	SSZ	NNP	O
as	as	IN	O
the	the	DT	O
positive	positive	JJ	O
control	control	NN	O
drug	drug	NN	O
.	.	.	O

Colitis	Colitis	NNP	O
was	be	VBD	O
induced	induce	VBN	O
by	by	IN	O
rectal	rectal	JJ	O
administration	administration	NN	O
of	of	IN	O
TNBS	TNBS	NNP	O
.	.	.	O

Our	-PRON-	PRP$	O
seven	seven	CD	O
pyridin-3-ol	pyridin-3-ol	NNP	O
compounds	compound	NNS	O
along	along	IN	O
with	with	IN	O
SSZ	SSZ	NNP	O
were	be	VBD	O
orally	orally	RB	O
administered	administer	VBN	O
once	once	RB	O
a	a	DT	O
day	day	NN	O
for	for	IN	O
five	five	CD	O
days	day	NNS	O
starting	start	VBG	O
one	one	CD	O
-	-	HYPH	O
day	day	NN	O
after	after	IN	O
administration	administration	NN	O
of	of	IN	O
TNBS	TNBS	NNP	O
at	at	IN	O
a	a	DT	O
dose	dose	NN	O
of	of	IN	O
1âmg	1âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
for	for	IN	O
seven	seven	CD	O
pyridin-3-ols	pyridin-3-ols	NNP	O
and	and	CC	O
300âmg	300âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
for	for	IN	O
SSZ	SSZ	NNP	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

After	after	IN	O
treatment	treatment	NN	O
with	with	IN	O
TNBS	TNBS	NNP	O
,	,	,	O
the	the	DT	O
rats	rat	NNS	O
showed	show	VBD	O
signs	sign	NNS	O
of	of	IN	O
colitis	colitis	NN	O
,	,	,	O
such	such	JJ	O
as	as	IN	O
body	body	NN	O
weight	weight	NN	O
decrease	decrease	NN	O
,	,	,	O
bloody	bloody	JJ	O
diarrhoea	diarrhoea	NNP	O
,	,	,	O
and	and	CC	O
sluggish	sluggish	JJ	O
and	and	CC	O
weak	weak	JJ	O
movement	movement	NN	O
.	.	.	O

Compared	compare	VBN	O
to	to	IN	O
the	the	DT	O
sham	sham	NN	O
-	-	HYPH	O
operated	operate	VBN	O
control	control	NNP	O
group	group	NN	O
,	,	,	O
the	the	DT	O
body	body	NN	O
weight	weight	NN	O
of	of	IN	O
the	the	DT	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
treated	treat	VBN	O
rats	rat	NNS	O
was	be	VBD	O
significantly	significantly	RB	O
reduced	reduce	VBN	O
and	and	CC	O
then	then	RB	O
increased	increase	VBD	O
gradually	gradually	RB	O
.	.	.	O

Colon	colon	NN	O
tissues	tissue	NNS	O
in	in	IN	O
the	the	DT	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
treated	treat	VBN	O
lesion	lesion	NN	O
site	site	NN	O
showed	show	VBD	O
significant	significant	JJ	O
inflammation	inflammation	NN	O
,	,	,	O
as	as	IN	O
revealed	reveal	VBN	O
by	by	IN	O
oedema	oedema	NN	O
and	and	CC	O
adhesion	adhesion	NN	O
in	in	IN	O
gross	gross	JJ	O
morphology	morphology	NN	O
examination	examination	NN	O
and	and	CC	O
increased	increase	VBD	O
wet	wet	JJ	O
weight	weight	NN	O
per	per	IN	O
colon	colon	NN	O
length	length	NN	O
.	.	.	O

As	as	IN	O
a	a	DT	O
macroscopic	macroscopic	JJ	O
marker	marker	NN	O
to	to	TO	O
represent	represent	VB	O
a	a	DT	O
disease	disease	NN	O
phenotype	phenotype	NN	O
,	,	,	O
we	-PRON-	PRP	O
measured	measure	VBD	O
the	the	DT	O
recovery	recovery	NN	O
level	level	NN	O
in	in	IN	O
body-	body-	NN	O
and	and	CC	O
colon	colon	NN	O
-	-	HYPH	O
weights	weight	NNS	O
upon	upon	IN	O
drug	drug	NN	O
treatment	treatment	NN	O
Figure	figure	NN	O
3	3	CD	O
.	.	.	O

Oral	oral	JJ	O
administration	administration	NN	O
of	of	IN	O
rats	rat	NNS	O
with	with	IN	O
compounds	compound	NNS	O
,	,	,	O
13âb	13âb	CD	O
,	,	,	O
14c	14c	NNS	O
,	,	,	O
14j	14j	NNS	O
,	,	,	O
14k	14k	NNS	O
,	,	,	O
14n	14n	NNS	O
,	,	,	O
18c	18c	NNS	O
,	,	,	O
or	or	CC	O
18d	18d	NNS	O
1âmg	1âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
significantly	significantly	RB	O
restored	restore	VBD	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
body	body	NN	O
weight	weight	NN	O
loss	loss	NN	O
Figure	figure	NN	O
3(A	3(a	NN	O
.	.	.	O

The	the	DT	O
recovery	recovery	NN	O
rate	rate	NN	O
by	by	IN	O
the	the	DT	O
compounds	compound	NNS	O
1âmg	1âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
ranged	range	VBD	O
from	from	IN	O
25	25	CD	O
%	%	NN	O
to	to	IN	O
98.9	98.9	CD	O
%	%	NN	O
,	,	,	O
among	among	IN	O
which	which	WDT	O
compound	compound	NN	O
14n	14n	NNS	O
was	be	VBD	O
the	the	DT	O
most	most	RBS	O
excellent	excellent	JJ	O
.	.	.	O

The	the	DT	O
recovery	recovery	NN	O
rate	rate	NN	O
of	of	IN	O
SSZ	SSZ	NNP	O
300âmg	300âmg	CD	O
/	/	SYM	O
kg	kg	NNP	O
,	,	,	O
a	a	DT	O
positive	positive	JJ	O
control	control	NN	O
,	,	,	O
was	be	VBD	O
48.8	48.8	CD	O
%	%	NN	O
.	.	.	O

Colon	colon	NN	O
weight	weight	NN	O
recovery	recovery	NN	O
was	be	VBD	O
between	between	IN	O
50.3	50.3	CD	O
%	%	NN	O
and	and	CC	O
94.9	94.9	CD	O
%	%	NN	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
better	well	JJR	O
than	than	IN	O
the	the	DT	O
body	body	NN	O
weight	weight	NN	O
recovery	recovery	NN	O
in	in	IN	O
most	most	JJS	O
cases	case	NNS	O
of	of	IN	O
oral	oral	JJ	O
administration	administration	NN	O
of	of	IN	O
the	the	DT	O
compounds	compound	NNS	O
including	include	VBG	O
sulfasalazine	sulfasalazine	NN	O
Figure	figure	NN	O
3(A	3(a	NN	O
.	.	.	O

Compound	compound	NN	O
14n	14n	NNS	O
1âmg	1âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
was	be	VBD	O
the	the	DT	O
most	most	RBS	O
effective	effective	JJ	O
in	in	IN	O
colon	colon	NN	O
weight	weight	NN	O
recovery	recovery	NN	O
as	as	IN	O
in	in	IN	O
the	the	DT	O
case	case	NN	O
of	of	IN	O
body	body	NN	O
weight	weight	NN	O
recovery	recovery	NN	O
.	.	.	O

In	in	IN	O
addition	addition	NN	O
,	,	,	O
the	the	DT	O
myeloperoxidase	myeloperoxidase	NN	O
MPO	MPO	NNP	O
level	level	VBP	O
in	in	IN	O
colon	colon	NN	O
tissues	tissue	NNS	O
,	,	,	O
which	which	WDT	O
is	be	VBZ	O
directly	directly	RB	O
related	relate	VBN	O
to	to	IN	O
neutrophil	neutrophil	NN	O
infiltration	infiltration	NN	O
into	into	IN	O
tissues	tissue	NNS	O
and	and	CC	O
serves	serve	VBZ	O
as	as	IN	O
a	a	DT	O
biochemical	biochemical	JJ	O
marker	marker	NN	O
of	of	IN	O
inflammation	inflammation	NN	B
,	,	,	O
was	be	VBD	O
examined	examine	VBN	O
.	.	.	O

TNBS	tnbs	NN	O
treatment	treatment	NN	O
induced	induce	VBD	O
a	a	DT	O
tremendous	tremendous	JJ	O
increase	increase	NN	O
in	in	IN	O
MPO	MPO	NNP	O
activity	activity	NN	O
Figure	Figure	NNP	O
4	4	CD	O
,	,	,	O
and	and	CC	O
the	the	DT	O
increase	increase	NN	O
was	be	VBD	O
significantly	significantly	RB	O
suppressed	suppress	VBN	O
by	by	IN	O
oral	oral	JJ	O
administration	administration	NN	O
with	with	IN	O
compounds	compound	NNS	O
1âmg	1âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
.	.	.	O

The	the	DT	O
order	order	NN	O
of	of	IN	O
the	the	DT	O
compounds	compound	NNS	O
having	have	VBG	O
excellent	excellent	JJ	O
effects	effect	NNS	O
was	be	VBD	O
14n	14n	NNS	O
,	,	,	O
14k	14k	NNS	O
,	,	,	O
14c	14c	NNS	O
,	,	,	O
14j	14j	NNS	O
,	,	,	O
13âb	13âb	CD	O
,	,	,	O
18c	18c	NNS	O
,	,	,	O
and	and	CC	O
18d	18d	NNS	O
,	,	,	O
demonstrating	demonstrate	VBG	O
the	the	DT	O
significant	significant	JJ	O
efficacy	efficacy	NN	O
of	of	IN	O
the	the	DT	O
new	new	JJ	O
scaffold	scaffold	NN	O
.	.	.	O

Recovery	recovery	NN	O
effects	effect	NNS	O
of	of	IN	O
compounds	compound	NNS	O
on	on	IN	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
rat	rat	NN	O
colitis	colitis	NN	O
,	,	,	O
body	body	NN	O
and	and	CC	O
colon	colon	NN	O
weights	weight	NNS	O
,	,	,	O
and	and	CC	O
MPO	MPO	NNP	O
activity	activity	NN	O
.	.	.	O

Colitis	Colitis	NNP	O
was	be	VBD	O
induced	induce	VBN	O
by	by	IN	O
rectal	rectal	JJ	O
administration	administration	NN	O
of	of	IN	O
TNBS	TNBS	NNP	O
,	,	,	O
and	and	CC	O
sham	sham	NNP	O
group	group	NNP	O
received	receive	VBD	O
vehicle	vehicle	NN	O
50	50	CD	O
%	%	NN	O
ethanol	ethanol	NN	O
in	in	IN	O
the	the	DT	O
same	same	JJ	O
route	route	NN	O
.	.	.	O

Compounds	compound	NNS	O
1âmg	1âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
and	and	CC	O
SSZ	SSZ	NNP	O
300âmg	300âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
were	be	VBD	O
given	give	VBN	O
orally	orally	RB	O
1âday	1âday	CD	O
after	after	IN	O
TNBS	TNBS	NNP	O
treatment	treatment	NN	O
.	.	.	O

Data	datum	NNS	O
represent	represent	VBP	O
the	the	DT	O
meanâÂ±âSEM	meanâÂ±âSEM	NNP	O
for	for	IN	O
five	five	CD	O
rats	rat	NNS	O
per	per	IN	O
group	group	NN	O
.	.	.	O

A	a	DT	O
Body	body	NN	O
weight	weight	NN	O
was	be	VBD	O
recorded	record	VBN	O
daily	daily	RB	O
from	from	IN	O
day	day	NN	O
0	0	CD	O
to	to	IN	O
day	day	NN	O
5	5	CD	O
,	,	,	O
and	and	CC	O
body	body	NN	O
weight	weight	NN	O
recovery	recovery	NN	O
was	be	VBD	O
calculated	calculate	VBN	O
based	base	VBN	O
on	on	IN	O
the	the	DT	O
last	last	JJ	O
day	day	NN	O
measurement	measurement	NN	O
.	.	.	O

Colon	colon	NN	O
wet	wet	JJ	O
weight	weight	NN	O
distal	distal	JJ	O
5â6âcm	5â6âcm	NNP	O
segment	segment	NN	O
was	be	VBD	O
measured	measure	VBN	O
right	right	RB	O
after	after	IN	O
dissection	dissection	NN	O
of	of	IN	O
the	the	DT	O
colon	colon	NN	O
.	.	.	O

#	#	$	O
pâ<â0.05	pâ<â0.05	NNP	O
compared	compare	VBN	O
to	to	IN	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
treated	treat	VBN	O
group	group	NN	O
.	.	.	O

$	$	$	O
pâ<â0.05	pâ<â0.05	NN	O
compared	compare	VBN	O
to	to	IN	O
SSZ	SSZ	NNP	O
-	-	HYPH	O
treated	treat	VBN	O
group	group	NN	O
.	.	.	O

B	b	NN	O
MPO	MPO	NNP	O
level	level	NN	O
of	of	IN	O
colon	colon	NN	O
tissues	tissue	NNS	O
*	*	NFP	O
pâ<â0.05	pâ<â0.05	NN	O
compared	compare	VBN	O
to	to	IN	O
sham	sham	NNP	O
-	-	HYPH	O
operated	operate	VBN	O
control	control	NN	O
group	group	NN	O
.	.	.	O

#	#	$	O
pâ<â0.05	pâ<â0.05	NNP	O
compared	compare	VBN	O
to	to	IN	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
treated	treat	VBN	O
group	group	NN	O
.	.	.	O

Inhibitory	inhibitory	NN	O
effects	effect	NNS	O
of	of	IN	O
compounds	compound	NNS	O
on	on	IN	O
expressions	expression	NNS	O
of	of	IN	O
inflammatory	inflammatory	JJ	O
cytokines	cytokine	NNS	O
and	and	CC	O
epithelial	epithelial	JJ	O
junction	junction	NN	O
molecules	molecule	NNS	O
.	.	.	O

Total	total	JJ	O
protein	protein	NN	O
extracts	extract	NNS	O
from	from	IN	O
colon	colon	NN	O
tissues	tissue	NNS	O
homogenates	homogenate	NNS	O
were	be	VBD	O
used	use	VBN	O
for	for	IN	O
detecting	detect	VBG	O
the	the	DT	O
protein	protein	NN	O
expression	expression	NN	O
of	of	IN	O
inflammatory	inflammatory	JJ	O
mediators	mediator	NNS	O
,	,	,	O
TNFÎ±	TNFÎ±	NNP	O
,	,	,	O
IL-6	il-6	JJ	O
,	,	,	O
and	and	CC	O
IL-1Î²	IL-1Î²	NNP	O
,	,	,	O
and	and	CC	O
junction	junction	NN	O
molecules	molecule	NNS	O
,	,	,	O
E	E	NNP	O
-	-	NN	O
cadherin	cadherin	NNP	O
,	,	,	O
claudin-2	claudin-2	NNP	O
,	,	,	O
claudin-3	claudin-3	NNP	O
,	,	,	O
and	and	CC	O
ZO-1	ZO-1	NNP	O
.	.	.	O

The	the	DT	O
bar	bar	NN	O
graphs	graphs	NN	O
represent	represent	VBP	O
the	the	DT	O
meanâÂ±âSEM	meanâÂ±âSEM	NNP	O
of	of	IN	O
protein	protein	NN	O
expression	expression	NN	O
quantified	quantify	VBN	O
in	in	IN	O
three	three	CD	O
independent	independent	JJ	O
experiments	experiment	NNS	O
.	.	.	O

*	*	NFP	O
pâ<â0.05	pâ<â0.05	NNP	O
,	,	,	O
compared	compare	VBN	O
with	with	IN	O
vehicle	vehicle	NN	O
-	-	HYPH	O
treated	treat	VBN	O
control	control	NN	O
group	group	NN	O
.	.	.	O

#	#	NNP	O
pâ<â0.05	pâ<â0.05	NNP	O
,	,	,	O
compared	compare	VBN	O
with	with	IN	O
the	the	DT	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
treated	treat	VBN	O
group	group	NN	O
.	.	.	O

Although	although	IN	O
the	the	DT	O
fundamental	fundamental	JJ	O
molecular	molecular	JJ	O
targets	target	NNS	O
of	of	IN	O
the	the	DT	O
compounds	compound	NNS	O
responsible	responsible	JJ	O
for	for	IN	O
the	the	DT	O
phenotype	phenotype	NN	O
are	be	VBP	O
yet	yet	RB	O
to	to	TO	O
be	be	VB	O
investigated	investigate	VBN	O
,	,	,	O
we	-PRON-	PRP	O
further	further	RB	O
examined	examine	VBD	O
in	in	IN	O
this	this	DT	O
study	study	NN	O
the	the	DT	O
inhibitory	inhibitory	JJ	O
effects	effect	NNS	O
of	of	IN	O
the	the	DT	O
compounds	compound	NNS	O
on	on	IN	O
the	the	DT	O
expression	expression	NN	O
levels	level	NNS	O
of	of	IN	O
cytokines	cytokine	NNS	O
responsible	responsible	JJ	O
for	for	IN	O
the	the	DT	O
inflammatory	inflammatory	JJ	O
response	response	NN	O
.	.	.	O

It	-PRON-	PRP	O
will	will	MD	O
provide	provide	VB	O
more	more	JJR	O
consistency	consistency	NN	O
to	to	IN	O
our	-PRON-	PRP$	O
mechanism	mechanism	NN	O
based	base	VBN	O
on	on	IN	O
the	the	DT	O
assay	assay	NN	O
against	against	IN	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±-induced	î±-induce	VBN	O
cell	cell	NN	O
adhesion	adhesion	NN	O
.	.	.	O

In	in	IN	O
rat	rat	NN	O
colon	colon	NN	O
tissues	tissue	NNS	O
,	,	,	O
TNBS	TNBS	NNP	O
treatment	treatment	NN	O
significantly	significantly	RB	O
increased	increase	VBD	O
the	the	DT	O
expression	expression	NN	O
of	of	IN	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
,	,	,	O
IL-6	il-6	JJ	O
and	and	CC	O
IL-1Î²	IL-1Î²	NNP	O
.	.	.	O

The	the	DT	O
expression	expression	NN	O
level	level	NN	O
of	of	IN	O
IL-10	IL-10	NNP	O
and	and	CC	O
TGF	TGF	NNP	O
-	-	HYPH	O
Î²	Î²	NNP	O
which	which	WDT	O
are	be	VBP	O
known	know	VBN	O
to	to	TO	O
be	be	VB	O
secreted	secrete	VBN	O
by	by	IN	O
M2	M2	NNP	O
macrophages	macrophage	NNS	O
for	for	IN	O
termination	termination	NN	O
of	of	IN	O
inflammation	inflammation	NN	O
and	and	CC	O
tissue	tissue	NN	O
repair	repair	NN	B
,	,	,	B
,	,	,	O
were	be	VBD	O
also	also	RB	O
significantly	significantly	RB	O
increased	increase	VBN	O
in	in	IN	O
the	the	DT	O
inflamed	inflamed	JJ	O
colon	colon	NN	O
tissues	tissue	NNS	O
Figure	figure	NN	O
4(A	4(a	NN	O
,	,	,	O
B	b	NN	O
.	.	.	O

In	in	IN	O
contrast	contrast	NN	O
,	,	,	O
level	level	NN	O
of	of	IN	O
colon	colon	NN	O
epithelial	epithelial	JJ	O
junction	junction	NN	O
molecules	molecule	NNS	O
,	,	,	O
E	E	NNP	O
-	-	NN	O
cadherin	cadherin	NNP	O
,	,	,	O
Claudin-2	Claudin-2	NNP	O
,	,	,	O
Claudin-3	Claudin-3	NNP	O
and	and	CC	O
ZO-1	ZO-1	NNP	O
was	be	VBD	O
significantly	significantly	RB	O
reduced	reduce	VBN	O
by	by	IN	O
TNBS	TNBS	NNP	O
Figure	figure	NN	O
4(A	4(a	NN	O
,	,	,	O
C	C	NNP	O
.	.	.	O

However	however	RB	O
,	,	,	O
oral	oral	JJ	O
administration	administration	NN	O
of	of	IN	O
compounds	compound	NNS	O
,	,	,	O
13b	13b	NNS	O
,	,	,	O
14c	14c	NNS	O
,	,	,	O
14j	14j	NNS	O
,	,	,	O
14k	14k	NNS	O
,	,	,	O
14n	14n	NNS	O
,	,	,	O
18c	18c	NNS	O
,	,	,	O
or	or	CC	O
18d	18d	NNS	O
1âmg	1âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
significantly	significantly	RB	O
restored	restore	VBD	O
the	the	DT	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
altered	alter	VBN	O
protein	protein	NN	O
expressions	expression	NNS	O
of	of	IN	O
junctional	junctional	JJ	O
molecules	molecule	NNS	O
.	.	.	O

All	all	PDT	O
these	these	DT	O
changes	change	NNS	O
consistently	consistently	RB	O
and	and	CC	O
strongly	strongly	RB	O
support	support	VBP	O
the	the	DT	O
anti	anti	JJ	O
-	-	JJ	O
IBD	ibd	JJ	O
activity	activity	NN	O
of	of	IN	O
our	-PRON-	PRP$	O
compounds	compound	NNS	O
.	.	.	O

Indeed	indeed	RB	O
,	,	,	O
the	the	DT	O
inhibitory	inhibitory	JJ	O
effects	effect	NNS	O
of	of	IN	O
compounds	compound	NNS	O
,	,	,	O
14c	14c	NNS	O
,	,	,	O
14j	14j	NNS	O
,	,	,	O
14k	14k	NNS	O
,	,	,	O
and	and	CC	O
14n	14n	NNS	O
1âmg	1âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
was	be	VBD	O
much	much	RB	O
stronger	strong	JJR	O
than	than	IN	O
that	that	DT	O
of	of	IN	O
300âmg	300âmg	CD	O
/	/	SYM	O
kg	kg	NNP	O
SSZ	SSZ	NNP	O
.	.	.	O

Next	next	RB	O
,	,	,	O
we	-PRON-	PRP	O
also	also	RB	O
examined	examine	VBD	O
whether	whether	IN	O
NLRP3	NLRP3	NNP	O
inflammasome	inflammasome	NNP	O
,	,	,	O
which	which	WDT	O
plays	play	VBZ	O
an	an	DT	O
important	important	JJ	O
role	role	NN	O
in	in	IN	O
IL-1Î²	IL-1Î²	NNP	O
production	production	NN	B
,	,	,	O
was	be	VBD	O
suppressed	suppress	VBN	O
by	by	IN	O
the	the	DT	O
compounds	compound	NNS	O
.	.	.	O

TNBS	TNBS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
alteration	alteration	NN	O
of	of	IN	O
NLRP3	NLRP3	NNP	O
inflammasome	inflammasome	NNP	O
components	component	NNS	O
,	,	,	O
NLRP3	nlrp3	NN	O
,	,	,	O
pro	pro	JJ	O
-	-	JJ	O
caspase-1	caspase-1	NNP	B
,	,	,	O
and	and	CC	O
cleaved	cleave	VBD	O
and	and	CC	O
active	active	JJ	O
caspase-1	caspase-1	NNP	O
,	,	,	O
were	be	VBD	O
blocked	block	VBN	O
by	by	IN	O
compounds	compound	NNS	O
,	,	,	O
13b	13b	NNS	O
,	,	,	O
14c	14c	NNS	O
,	,	,	O
14j	14j	NNS	O
,	,	,	O
14k	14k	NNS	O
,	,	,	O
14n	14n	NNS	O
,	,	,	O
18c	18c	NNS	O
,	,	,	O
or	or	CC	O
18d	18d	NNS	O
Figure	figure	NN	O
5	5	CD	O
.	.	.	O

Similar	similar	JJ	O
to	to	IN	O
the	the	DT	O
effects	effect	NNS	O
of	of	IN	O
the	the	DT	O
compounds	compound	NNS	O
on	on	IN	O
cytokine	cytokine	JJ	O
expressions	expression	NNS	O
,	,	,	O
14n	14n	NNS	O
exerted	exert	VBD	O
the	the	DT	O
strongest	strong	JJS	O
effect	effect	NN	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
followed	follow	VBN	O
by	by	IN	O
14c	14c	NNS	O
,	,	,	O
14j	14j	NNS	O
,	,	,	O
14k	14k	NNS	O
,	,	,	O
13b	13b	NNS	O
,	,	,	O
18c	18c	NNS	O
,	,	,	O
and	and	CC	O
18d	18d	NNS	O
.	.	.	O

Consistent	consistent	JJ	O
to	to	IN	O
the	the	DT	O
result	result	NN	O
of	of	IN	O
NLRP3	NLRP3	NNP	O
inflammasome	inflammasome	NNP	O
activation	activation	NN	O
,	,	,	O
IL-18	IL-18	NNP	O
level	level	NN	O
was	be	VBD	O
significantly	significantly	RB	O
increased	increase	VBN	O
in	in	IN	O
the	the	DT	O
colon	colon	NN	O
of	of	IN	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
treated	treat	VBN	O
rats	rat	NNS	O
,	,	,	O
and	and	CC	O
compounds	compound	NNS	O
,	,	,	O
13b	13b	NNS	O
,	,	,	O
14c	14c	NNS	O
,	,	,	O
14j	14j	NNS	O
,	,	,	O
14k	14k	NNS	O
,	,	,	O
14n	14n	NNS	O
,	,	,	O
18c	18c	NNS	O
,	,	,	O
and	and	CC	O
18d	18d	NFP	O
significantly	significantly	RB	O
inhibited	inhibit	VBD	O
the	the	DT	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
IL-18	IL-18	NNP	O
expression	expression	NN	O
.	.	.	O

NLRP3	NLRP3	NNP	O
inflammasome	inflammasome	NNP	O
formation	formation	NN	O
in	in	IN	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
treated	treat	VBN	O
rat	rat	NN	O
colon	colon	NN	O
was	be	VBD	O
suppressed	suppress	VBN	O
by	by	IN	O
the	the	DT	O
compounds	compound	NNS	O
.	.	.	O

Total	total	JJ	O
protein	protein	NN	O
extracts	extract	NNS	O
from	from	IN	O
colon	colon	NN	O
tissue	tissue	NN	O
homogenates	homogenate	NNS	O
were	be	VBD	O
used	use	VBN	O
for	for	IN	O
detection	detection	NN	O
of	of	IN	O
NLRP3	NLRP3	NNP	O
inflammasome	inflammasome	NNP	O
components	component	NNS	O
.	.	.	O

The	the	DT	O
bar	bar	NN	O
graphs	graphs	NN	O
represent	represent	VBP	O
the	the	DT	O
meanâÂ±âSEM	meanâÂ±âSEM	NNP	O
of	of	IN	O
protein	protein	NN	O
expression	expression	NN	O
quantified	quantify	VBN	O
in	in	IN	O
three	three	CD	O
independent	independent	JJ	O
experiments	experiment	NNS	O
.	.	.	O

*	*	NFP	O
pâ<â0.05	pâ<â0.05	NNP	O
,	,	,	O
compared	compare	VBN	O
with	with	IN	O
vehicle	vehicle	NN	O
-	-	HYPH	O
treated	treat	VBN	O
control	control	NN	O
group	group	NN	O
.	.	.	O

#	#	NNP	O
pâ<â0.05	pâ<â0.05	NNP	O
,	,	,	O
compared	compare	VBN	O
with	with	IN	O
the	the	DT	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
treated	treat	VBN	O
group	group	NN	O
.	.	.	O

In	in	IN	O
the	the	DT	O
colon	colon	NN	O
of	of	IN	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
treated	treat	VBN	O
rats	rat	NNS	O
,	,	,	O
nuclear	nuclear	JJ	O
factor	factor	NN	O
-	-	HYPH	O
kappa	kappa	NNP	O
B	B	NNP	O
NF	NF	NNP	O
-	-	HYPH	O
ÎºB	ÎºB	NNP	O
,	,	,	O
a	a	DT	O
transcription	transcription	NN	O
factor	factor	NN	O
associated	associate	VBN	O
with	with	IN	O
expression	expression	NN	O
of	of	IN	O
inflammatory	inflammatory	JJ	O
cytokines	cytokine	NNS	O
and	and	CC	O
NLRP3	NLRP3	NNP	O
inflammasome	inflammasome	NNP	O
was	be	VBD	O
increased	increase	VBN	O
,	,	,	O
while	while	IN	O
cytosolic	cytosolic	JJ	O
NF	NF	NNP	O
-	-	HYPH	O
ÎºB	îºb	NN	O
level	level	NN	O
was	be	VBD	O
decreased	decrease	VBN	O
in	in	RP	O
along	along	IN	O
with	with	IN	O
inhibitory	inhibitory	NN	O
-	-	HYPH	O
ÎºB	ÎºB	NNP	O
I	i	NN	O
-	-	HYPH	O
ÎºB	ÎºB	NNP	O
phosphorylation	phosphorylation	NN	O
.	.	.	O

However	however	RB	O
,	,	,	O
the	the	DT	O
compounds	compound	NNS	O
significantly	significantly	RB	O
suppressed	suppress	VBD	O
the	the	DT	O
nuclear	nuclear	JJ	O
translocation	translocation	NN	O
of	of	IN	O
NF	NF	NNP	O
-	-	HYPH	O
ÎºB	ÎºB	NNP	O
Figure	Figure	NNP	O
6	6	CD	O
.	.	.	O

Inhibitory	inhibitory	NN	O
effects	effect	NNS	O
of	of	IN	O
the	the	DT	O
compounds	compound	NNS	O
on	on	IN	O
the	the	DT	O
nuclear	nuclear	JJ	O
translocation	translocation	NN	O
of	of	IN	O
NF	NF	NNP	O
-	-	HYPH	O
ÎºB	ÎºB	NNP	O
in	in	IN	O
along	along	IN	O
with	with	IN	O
increase	increase	NN	O
in	in	IN	O
cytosolic	cytosolic	JJ	O
phospho	phospho	NN	O
-	-	:	O
I	-PRON-	PRP	O
-	-	HYPH	O
ÎºB.	ÎºB.	NNP	O
Cytosolic	Cytosolic	NNP	O
and	and	CC	O
nuclear	nuclear	JJ	O
proteins	protein	NNS	O
extracted	extract	VBN	O
from	from	IN	O
colon	colon	NN	O
tissue	tissue	NN	O
homogenates	homogenate	NNS	O
were	be	VBD	O
used	use	VBN	O
for	for	IN	O
detection	detection	NN	O
of	of	IN	O
phospho	phospho	NN	O
-	-	:	O
I	I	NNP	O
-	-	HYPH	O
ÎºB	ÎºB	NNP	O
,	,	,	O
I	I	NNP	O
-	-	HYPH	O
ÎºB	ÎºB	NNP	O
,	,	,	O
and	and	CC	O
NF	NF	NNP	O
-	-	HYPH	O
ÎºB.	îºb.	NN	O
The	the	DT	O
bar	bar	NN	O
graphs	graphs	NN	O
represent	represent	VBP	O
the	the	DT	O
meanâÂ±âSEM	meanâÂ±âSEM	NNP	O
of	of	IN	O
protein	protein	NN	O
expression	expression	NN	O
quantified	quantify	VBN	O
in	in	IN	O
three	three	CD	O
independent	independent	JJ	O
experiments	experiment	NNS	O
.	.	.	O

*	*	NFP	O
pâ<â0.05	pâ<â0.05	NNP	O
,	,	,	O
compared	compare	VBN	O
with	with	IN	O
vehicle	vehicle	NN	O
-	-	HYPH	O
treated	treat	VBN	O
control	control	NN	O
group	group	NN	O
.	.	.	O

#	#	NNP	O
pâ<â0.05	pâ<â0.05	NNP	O
,	,	,	O
compared	compare	VBN	O
with	with	IN	O
the	the	DT	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
treated	treat	VBN	O
group	group	NN	O
.	.	.	O

TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
is	be	VBZ	O
a	a	DT	O
critical	critical	JJ	O
player	player	NN	O
in	in	IN	O
the	the	DT	O
pathogenesis	pathogenesis	NN	O
of	of	IN	O
IBD	IBD	NNP	O
,	,	,	O
which	which	WDT	O
is	be	VBZ	O
supported	support	VBN	O
by	by	IN	O
the	the	DT	O
most	most	RBS	O
efficacious	efficacious	JJ	O
effects	effect	NNS	O
of	of	IN	O
anti	anti	JJ	O
-	-	JJ	O
TNF	tnf	JJ	O
-	-	HYPH	O
Î±	Î±	NNP	O
biologics	biologic	NNS	O
in	in	IN	O
the	the	DT	O
clinic	clinic	NN	B
.	.	.	O

Based	base	VBN	O
on	on	IN	O
the	the	DT	O
notion	notion	NN	O
,	,	,	O
we	-PRON-	PRP	O
examined	examine	VBD	O
anti	anti	JJ	O
-	-	JJ	O
IBD	ibd	JJ	O
activity	activity	NN	O
of	of	IN	O
various	various	JJ	O
compounds	compound	NNS	O
against	against	IN	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±-induced	î±-induce	VBN	O
monocyte	monocyte	NN	O
adhesion	adhesion	NN	O
to	to	IN	O
colonic	colonic	JJ	O
epithelial	epithelial	JJ	O
cells	cell	NNS	O
,	,	,	O
an	an	DT	O
in	in	FW	O
vitro	vitro	FW	O
model	model	NN	O
of	of	IN	O
initial	initial	JJ	O
phase	phase	NN	O
of	of	IN	O
colitis	colitis	NN	O
.	.	.	O

In	in	IN	O
the	the	DT	O
previous	previous	JJ	O
reports	report	NNS	O
,	,	,	O
we	-PRON-	PRP	O
found	find	VBD	O
that	that	IN	O
6-amino-2,4,5-trimethylpyridin-3-ol	6-amino-2,4,5-trimethylpyridin-3-ol	CD	O
scaffold	scaffold	NNP	O
was	be	VBD	O
effective	effective	JJ	O
against	against	IN	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±-induced	î±-induce	VBN	O
cell	cell	NN	O
adhesion	adhesion	NN	O
between	between	IN	O
monocyte	monocyte	NN	O
and	and	CC	O
colon	colon	NN	O
epithelial	epithelial	JJ	O
cells	cell	NNS	O
and	and	CC	O
against	against	IN	O
severe	severe	JJ	O
inflammation	inflammation	NN	O
of	of	IN	O
colon	colon	NN	O
induced	induce	VBN	O
by	by	IN	O
TNBS	TNBS	NNP	O
.	.	.	O

Among	among	IN	O
the	the	DT	O
6-aminopyridin-3-ols	6-aminopyridin-3-ols	CD	O
prepared	prepare	VBN	O
,	,	,	O
compounds	compound	NNS	O
AâââC	AâââC	NNP	O
showed	show	VBD	O
excellent	excellent	JJ	O
efficacy	efficacy	NN	O
in	in	IN	O
in	in	IN	O
vivo	vivo	NN	O
experiments	experiment	NNS	B
,	,	,	B
.	.	.	O

Structurally	structurally	RB	O
speaking	speak	VBG	O
,	,	,	O
these	these	DT	O
strong	strong	JJ	O
analogues	analogue	NNS	O
AâââC	AâââC	NNP	O
contain	contain	VB	O
some	some	DT	O
sort	sort	NN	O
of	of	IN	O
sp2-carbon	sp2-carbon	NN	O
indicated	indicate	VBN	O
with	with	IN	O
arrows	arrow	NNS	O
attached	attach	VBN	O
to	to	IN	O
C(6)-nitrogen	c(6)-nitrogen	NN	O
.	.	.	O

In	in	IN	O
this	this	DT	O
study	study	NN	O
,	,	,	O
we	-PRON-	PRP	O
decided	decide	VBD	O
to	to	TO	O
further	further	RB	O
explore	explore	VB	O
the	the	DT	O
chemical	chemical	NN	O
space	space	NN	O
of	of	IN	O
the	the	DT	O
substituents	substituent	NNS	O
on	on	IN	O
C(6)-position	c(6)-position	NN	O
.	.	.	O

First	first	RB	O
,	,	,	O
we	-PRON-	PRP	O
wondered	wonder	VBD	O
if	if	IN	O
nitrogen	nitrogen	NN	O
is	be	VBZ	O
essential	essential	JJ	O
on	on	IN	O
C(6)-position	c(6)-position	NN	O
for	for	IN	O
activity	activity	NN	O
and	and	CC	O
decided	decide	VBD	O
to	to	TO	O
replace	replace	VB	O
it	-PRON-	PRP	O
with	with	IN	O
another	another	DT	O
heteroatom	heteroatom	NN	O
,	,	,	O
oxygen	oxygen	NN	O
.	.	.	O

The	the	DT	O
resulting	result	VBG	O
alkoxy	alkoxy	JJ	O
analogues	analogue	NNS	O
8aâ8f	8aâ8f	NFP	O
showed	show	VBD	O
low	low	JJ	O
to	to	IN	O
mediocre	mediocre	JJ	O
range	range	NN	O
activity	activity	NN	O
in	in	IN	O
our	-PRON-	PRP$	O
in	in	FW	O
vitro	vitro	FW	O
assay	assay	NNP	O
and	and	CC	O
it	-PRON-	PRP	O
seems	seem	VBZ	O
that	that	IN	O
nitrogen	nitrogen	NN	O
is	be	VBZ	O
quite	quite	RB	O
necessary	necessary	JJ	O
for	for	IN	O
the	the	DT	O
position	position	NN	O
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
the	the	DT	O
next	next	JJ	O
approach	approach	NN	O
we	-PRON-	PRP	O
decided	decide	VBD	O
to	to	TO	O
conduct	conduct	VB	O
based	base	VBN	O
on	on	IN	O
the	the	DT	O
activity	activity	NN	O
of	of	IN	O
the	the	DT	O
alkoxy	alkoxy	JJ	O
-	-	HYPH	O
analogues	analogue	NNS	O
is	be	VBZ	O
to	to	TO	O
keep	keep	VB	O
nitrogen	nitrogen	NN	O
on	on	IN	O
C(6)-position	c(6)-position	NN	O
and	and	CC	O
instead	instead	RB	O
introduce	introduce	VB	O
carbonyl	carbonyl	NN	O
-	-	HYPH	O
like	like	JJ	O
functional	functional	JJ	O
groups	group	NNS	O
attached	attach	VBN	O
to	to	IN	O
C(6)-nitrogen	c(6)-nitrogen	NN	O
as	as	IN	O
an	an	DT	O
alteration	alteration	NN	O
of	of	IN	O
sp2-carbon	sp2-carbon	NNP	O
shown	show	VBN	O
in	in	IN	O
previous	previous	JJ	O
papers	paper	NNS	O
.	.	.	O

This	this	DT	O
type	type	NN	O
of	of	IN	O
analogues	analogue	NNS	O
include	include	VBP	O
ureido	ureido	NNP	O
11	11	CD	O
,	,	,	O
thioureido	thioureido	NNP	O
12	12	CD	O
,	,	,	O
carbamato	carbamato	NNP	O
16	16	CD	O
and	and	CC	O
sulfonamido	sulfonamido	NNP	O
18	18	CD	O
analogues	analogue	NNS	O
.	.	.	O

As	as	IN	O
a	a	DT	O
result	result	NN	O
,	,	,	O
many	many	JJ	O
compounds	compound	NNS	O
shown	show	VBN	O
in	in	IN	O
this	this	DT	O
paper	paper	NN	O
were	be	VBD	O
found	find	VBN	O
to	to	TO	O
have	have	VB	O
very	very	RB	O
strong	strong	JJ	O
activity	activity	NN	O
.	.	.	O

In	in	IN	O
vitro	vitro	FW	O
,	,	,	O
some	some	DT	O
compounds	compound	NNS	O
including	include	VBG	O
thiourea	thiourea	NNP	O
and	and	CC	O
sulphonamide	sulphonamide	VB	O
analogues	analogue	NNS	O
showed	show	VBD	O
up	up	IN	O
to	to	TO	O
93	93	CD	O
%	%	NN	O
inhibition	inhibition	NN	O
against	against	IN	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±-induced	î±-induce	VBN	O
cell	cell	NN	O
adhesion	adhesion	NN	O
at	at	IN	O
1âÎ¼M	1âî¼m	CD	O
concentration	concentration	NN	O
.	.	.	O

It	-PRON-	PRP	O
is	be	VBZ	O
the	the	DT	O
highest	high	JJS	O
in	in	IN	O
vitro	vitro	FW	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
measured	measure	VBN	O
with	with	IN	O
pyridin-3-ol	pyridin-3-ol	LS	O
analogues	analogue	NNS	O
we	-PRON-	PRP	O
synthesised	synthesise	VBD	O
so	so	RB	O
far	far	RB	O
.	.	.	O

The	the	DT	O
order	order	NN	O
of	of	IN	O
the	the	DT	O
compounds	compound	NNS	O
having	have	VBG	O
excellent	excellent	JJ	O
in	in	FW	O
vitro	vitro	FW	O
effects	effect	NNS	O
was	be	VBD	O
14n	14n	NNS	O
,	,	,	O
14k	14k	NNS	O
,	,	,	O
14c	14c	NNS	O
,	,	,	O
14j	14j	NNS	O
,	,	,	O
13b	13b	NNS	O
,	,	,	O
18c	18c	NNS	O
,	,	,	O
and	and	CC	O
18d	18d	NNS	O
.	.	.	O

Such	such	JJ	O
in	in	IN	O
vitro	vitro	FW	O
activity	activity	NN	O
of	of	IN	O
the	the	DT	O
compounds	compound	NNS	O
was	be	VBD	O
consistent	consistent	JJ	O
with	with	IN	O
in	in	IN	O
vivo	vivo	NNP	O
anti	anti	JJ	O
-	-	JJ	O
colitis	colitis	JJ	O
efficacy	efficacy	NN	O
1âmg	1âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
on	on	IN	O
colitis	colitis	NN	O
signs	sign	NNS	O
and	and	CC	O
biochemical	biochemical	JJ	O
inflammatory	inflammatory	JJ	O
markers	marker	NNS	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
much	much	RB	O
better	well	JJR	O
than	than	IN	O
SSZ	SSZ	NNP	O
300âmg	300âmg	CD	O
/	/	SYM	O
kg	kg	NNS	O
.	.	.	O

Among	among	IN	O
high	high	JJ	O
activity	activity	NN	O
compounds	compound	NNS	O
,	,	,	O
14n	14n	NNS	O
,	,	,	O
a	a	DT	O
thiourea	thiourea	NNP	O
analogue	analogue	NN	O
,	,	,	O
showed	show	VBD	O
the	the	DT	O
best	good	JJS	O
in	in	IN	O
vivo	vivo	NNP	O
activity	activity	NN	O
represented	represent	VBN	O
by	by	IN	O
macroscopic	macroscopic	JJ	O
parameters	parameter	NNS	O
such	such	JJ	O
as	as	IN	O
almost	almost	RB	O
complete	complete	JJ	O
recovery	recovery	NN	O
of	of	IN	O
colon	colon	NN	O
and	and	CC	O
body	body	NN	O
weights	weight	NNS	O
95	95	CD	O
%	%	NN	O
and	and	CC	O
99	99	CD	O
%	%	NN	O
,	,	,	O
respectively	respectively	RB	O
in	in	IN	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
colitis	colitis	NN	O
rat	rat	NN	O
model	model	NN	O
.	.	.	O

Although	although	IN	O
the	the	DT	O
exact	exact	JJ	O
aetiology	aetiology	NN	O
of	of	IN	O
IBD	IBD	NNP	O
has	have	VBZ	O
not	not	RB	O
yet	yet	RB	O
been	be	VBN	O
clarified	clarify	VBN	O
,	,	,	O
a	a	DT	O
defective	defective	JJ	O
innate	innate	JJ	O
immune	immune	JJ	O
response	response	NN	O
seems	seem	VBZ	O
to	to	TO	O
play	play	VB	O
a	a	DT	O
critical	critical	JJ	O
role	role	NN	O
in	in	IN	O
the	the	DT	O
chronic	chronic	JJ	O
gut	gut	NN	O
inflammation	inflammation	NN	B
.	.	.	O

Our	-PRON-	PRP$	O
current	current	JJ	O
study	study	NN	O
showing	show	VBG	O
an	an	DT	O
increase	increase	NN	O
in	in	IN	O
the	the	DT	O
expressions	expression	NNS	O
of	of	IN	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
,	,	,	O
IL-6	il-6	JJ	O
,	,	,	O
and	and	CC	O
IL-1Î²	IL-1Î²	NNP	O
,	,	,	O
referred	refer	VBD	O
to	to	IN	O
as	as	RB	O
troika	troika	RB	O
of	of	IN	O
pro	pro	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
cytokines	cytokine	NNS	O
in	in	IN	O
colon	colon	NN	O
tissues	tissue	NNS	O
of	of	IN	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
treated	treat	VBN	O
rats	rat	NNS	O
,	,	,	O
was	be	VBD	O
consistent	consistent	JJ	O
with	with	IN	O
many	many	JJ	O
previous	previous	JJ	O
studies	study	NNS	O
in	in	IN	O
IBD	IBD	NNP	O
patients	patient	NNS	O
as	as	RB	O
well	well	RB	O
as	as	IN	O
animal	animal	NN	O
models	model	NNS	O
of	of	IN	O
IBD	IBD	NNP	B
,	,	,	B
.	.	.	O

TNBS	tnbs	NN	O
treatment	treatment	NN	O
also	also	RB	O
significantly	significantly	RB	O
increased	increase	VBD	O
colonic	colonic	JJ	O
levels	level	NNS	O
of	of	IN	O
IL-10	IL-10	NNP	O
and	and	CC	O
TGF	TGF	NNP	O
-	-	HYPH	O
Î²	Î²	NNP	O
,	,	,	O
known	know	VBN	O
as	as	IN	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
cytokines	cytokine	NNS	O
.	.	.	O

Although	although	IN	O
the	the	DT	O
expression	expression	NN	O
level	level	NN	O
of	of	IN	O
IL-10	IL-10	NNP	O
in	in	IN	O
experimental	experimental	JJ	O
colitis	colitis	NN	O
is	be	VBZ	O
contradictory	contradictory	JJ	B
,	,	,	O
IL-10	IL-10	NNP	O
level	level	NN	O
may	may	MD	O
be	be	VB	O
related	relate	VBN	O
to	to	IN	O
the	the	DT	O
inflammatory	inflammatory	JJ	O
phase	phase	NN	O
,	,	,	O
increased	increase	VBD	O
at	at	IN	O
the	the	DT	O
initial	initial	JJ	O
phase	phase	NN	O
and	and	CC	O
returned	return	VBD	O
to	to	IN	O
baseline	baseline	JJ	O
level	level	NN	O
in	in	IN	O
the	the	DT	O
resolution	resolution	NN	O
phase	phase	NN	O
of	of	IN	O
inflammation	inflammation	NN	B
,	,	,	B
.	.	.	O

Oral	oral	JJ	O
treatments	treatment	NNS	O
with	with	IN	O
the	the	DT	O
compounds	compound	NNS	O
significantly	significantly	RB	O
suppressed	suppress	VBD	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
expressions	expression	NNS	O
of	of	IN	O
IL-10	IL-10	NNP	O
,	,	,	O
in	in	IN	O
addition	addition	NN	O
to	to	IN	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
,	,	,	O
IL-6	il-6	JJ	O
,	,	,	O
and	and	CC	O
IL-1Î²	IL-1Î²	NNP	O
in	in	IN	O
colon	colon	NN	O
tissues	tissue	NNS	O
,	,	,	O
indicating	indicate	VBG	O
that	that	IN	O
an	an	DT	O
anti	anti	JJ	O
-	-	JJ	O
colitis	colitis	JJ	O
activity	activity	NN	O
of	of	IN	O
the	the	DT	O
compounds	compound	NNS	O
led	lead	VBD	O
to	to	IN	O
the	the	DT	O
resolution	resolution	NN	O
phase	phase	NN	O
of	of	IN	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
inflammation	inflammation	NN	O
.	.	.	O

In	in	IN	O
the	the	DT	O
case	case	NN	O
of	of	IN	O
TGF	TGF	NNP	O
-	-	HYPH	O
Î²	Î²	NNP	O
,	,	,	O
its	-PRON-	PRP$	O
production	production	NN	O
is	be	VBZ	O
upregulated	upregulate	VBN	O
by	by	IN	O
bacteria	bacteria	NNS	O
,	,	,	O
viruses	virus	NNS	O
,	,	,	O
cytokines	cytokine	NNS	O
,	,	,	O
and	and	CC	O
dying	die	VBG	O
cells	cell	NNS	O
,	,	,	O
in	in	IN	O
an	an	DT	O
autocrine	autocrine	NN	O
or	or	CC	O
paracrine	paracrine	NN	O
manner	manner	NN	B
,	,	,	B
.	.	.	O

TGF	TGF	NNP	O
-	-	HYPH	O
Î²	Î²	NNP	O
suppresses	suppress	VBZ	O
inflammatory	inflammatory	JJ	O
responses	response	NNS	O
similar	similar	JJ	O
to	to	IN	O
IL-10	IL-10	NNP	O
,	,	,	O
although	although	IN	O
previous	previous	JJ	O
reports	report	NNS	O
on	on	IN	O
TGF	TGF	NNP	O
-	-	HYPH	O
Î²	î²	NN	O
expression	expression	NN	O
in	in	IN	O
IBD	IBD	NNP	O
have	have	VBP	O
shown	show	VBN	O
contradictory	contradictory	JJ	O
results	result	NNS	O
depending	depend	VBG	O
on	on	IN	O
active	active	JJ	O
or	or	CC	O
inactive	inactive	JJ	O
IBD	IBD	NNP	B
,	,	,	B
,	,	,	O
TGF	TGF	NNP	O
-	-	HYPH	O
Î²	î²	NN	O
levels	level	NNS	O
are	be	VBP	O
elevated	elevate	VBN	O
in	in	IN	O
inflamed	inflame	VBN	O
area	area	NN	O
of	of	IN	O
gut	gut	NNP	O
tissues	tissue	NNS	O
in	in	IN	O
IBD	IBD	NNP	B
.	.	.	O

Consistently	consistently	RB	O
,	,	,	O
our	-PRON-	PRP$	O
current	current	JJ	O
results	result	NNS	O
also	also	RB	O
showed	show	VBD	O
that	that	IN	O
TNBS	TNBS	NNP	O
induced	induce	VBN	O
TGF	TGF	NNP	O
-	-	HYPH	O
Î²	î²	NN	O
increase	increase	NN	O
in	in	IN	O
the	the	DT	O
colon	colon	NN	O
,	,	,	O
and	and	CC	O
oral	oral	JJ	O
administration	administration	NN	O
of	of	IN	O
the	the	DT	O
compounds	compound	NNS	O
significantly	significantly	RB	O
reduced	reduce	VBD	O
the	the	DT	O
level	level	NN	O
of	of	IN	O
TGF	TGF	NNP	O
-	-	HYPH	O
Î²	Î²	NNP	O
with	with	IN	O
the	the	DT	O
best	good	JJS	O
effects	effect	NNS	O
of	of	IN	O
14n	14n	NNS	O
,	,	,	O
14k	14k	NNS	O
,	,	,	O
14c	14c	NNS	O
,	,	,	O
and	and	CC	O
14j	14j	NNS	O
.	.	.	O

The	the	DT	O
innate	innate	JJ	O
immune	immune	JJ	O
system	system	NN	O
is	be	VBZ	O
activated	activate	VBN	O
by	by	IN	O
the	the	DT	O
pattern	pattern	NN	O
recognition	recognition	NN	O
receptors	receptor	NNS	O
PRRs	prr	NNS	O
which	which	WDT	O
recognise	recognise	VBP	O
pathogen	pathogen	NN	O
-	-	HYPH	O
associated	associate	VBN	O
molecular	molecular	JJ	O
patterns	pattern	NNS	O
PAMPs	PAMPs	NNP	O
or	or	CC	O
endogenous	endogenous	JJ	O
danger	danger	NN	O
-	-	HYPH	O
associated	associate	VBN	O
molecular	molecular	JJ	O
patterns	pattern	NNS	O
DAMPs	DAMPs	NNP	O
generated	generate	VBD	O
during	during	IN	O
cellular	cellular	JJ	O
injury	injury	NN	O
or	or	CC	O
tissue	tissue	NN	O
damage	damage	NN	B
.	.	.	O

PRRs	prr	NNS	O
comprise	comprise	VBP	O
the	the	DT	O
membrane	membrane	NN	O
-	-	HYPH	O
bound	bind	VBN	O
toll	toll	NN	O
-	-	HYPH	O
like	like	JJ	O
receptors	receptor	NNS	O
TLRs	TLRs	NNPS	O
and	and	CC	O
the	the	DT	O
cytosolic	cytosolic	NNP	O
sensory	sensory	JJ	O
protein	protein	NN	O
complexes	complex	NNS	O
such	such	JJ	O
as	as	IN	O
NOD	NOD	NNP	O
-	-	HYPH	O
like	like	JJ	O
receptors	receptor	NNS	O
NLR	NLR	NNP	O
)	)	-RRB-	B
.	.	.	O

NLRP3	NLRP3	NNP	O
,	,	,	O
an	an	DT	O
NLR	NLR	NNP	O
family	family	NN	O
member	member	NN	O
,	,	,	O
has	have	VBZ	O
been	be	VBN	O
highlighted	highlight	VBN	O
as	as	IN	O
a	a	DT	O
contributing	contribute	VBG	O
factor	factor	NN	O
in	in	IN	O
the	the	DT	O
pathogenesis	pathogenesis	NN	O
of	of	IN	O
IBD	IBD	NNP	B
.	.	.	O

NLRP3	NLRP3	NNP	O
mediates	mediate	VBZ	O
the	the	DT	O
assembly	assembly	NN	O
and	and	CC	O
activation	activation	NN	O
of	of	IN	O
the	the	DT	O
inflammasome	inflammasome	NN	O
,	,	,	O
a	a	DT	O
multi	multi	JJ	O
-	-	JJ	O
protein	protein	JJ	O
complex	complex	NN	O
,	,	,	O
which	which	WDT	O
recognises	recognise	VBZ	O
cellular	cellular	JJ	O
stresses	stress	NNS	O
and	and	CC	O
responds	respond	VBZ	O
to	to	IN	O
them	-PRON-	PRP	O
by	by	IN	O
activating	activate	VBG	O
caspase-1	caspase-1	NNP	O
.	.	.	O

Activated	Activated	NNP	O
caspase-1	caspase-1	NNP	O
converts	convert	VBZ	O
pro	pro	JJ	O
-	-	JJ	O
IL-1Î²	il-1î²	JJ	O
and	and	CC	O
pro	pro	JJ	O
-	-	JJ	O
IL-18	IL-18	NNP	O
into	into	IN	O
their	-PRON-	PRP$	O
active	active	JJ	O
forms	form	NNS	O
,	,	,	O
IL-1Î²	IL-1Î²	NNP	O
and	and	CC	O
IL-18	IL-18	NNP	O
,	,	,	O
and	and	CC	O
induces	induce	VBZ	O
pyroptosis	pyroptosis	NN	O
,	,	,	O
an	an	DT	O
inflammatory	inflammatory	JJ	O
form	form	NN	O
of	of	IN	O
cell	cell	NN	O
death	death	NN	B
.	.	.	O

In	in	IN	O
the	the	DT	O
present	present	JJ	O
study	study	NN	O
,	,	,	O
a	a	DT	O
significant	significant	JJ	O
increase	increase	NN	O
in	in	IN	O
NLRP3	NLRP3	NNP	O
and	and	CC	O
caspase-1	caspase-1	NNP	O
in	in	IN	O
colon	colon	NN	O
tissues	tissue	NNS	O
by	by	IN	O
TNBS	TNBS	NNP	O
treatment	treatment	NN	O
are	be	VBP	O
correlated	correlate	VBN	O
to	to	IN	O
a	a	DT	O
high	high	JJ	O
-	-	HYPH	O
level	level	NN	O
increase	increase	NN	O
in	in	IN	O
IL-1Î²	IL-1Î²	NNP	O
and	and	CC	O
IL-18	IL-18	NNP	O
.	.	.	O

In	in	IN	O
addition	addition	NN	O
,	,	,	O
the	the	DT	O
correlation	correlation	NN	O
between	between	IN	O
casapase-1	casapase-1	NNP	O
increase	increase	NN	O
and	and	CC	O
the	the	DT	O
significant	significant	JJ	O
reduction	reduction	NN	O
in	in	IN	O
junction	junction	NN	O
molecules	molecule	NNS	O
,	,	,	O
E	E	NNP	O
-	-	HYPH	O
cadherin	cadherin	NNP	O
,	,	,	O
claudins	claudin	NNS	O
,	,	,	O
and	and	CC	O
ZO-1	ZO-1	NNP	O
in	in	IN	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
treated	treat	VBN	O
colon	colon	NN	O
implicates	implicate	VBZ	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
mucosal	mucosal	NN	O
damage	damage	NN	O
through	through	IN	O
pyroptosis	pyroptosis	NN	O
.	.	.	O

Inhibitory	inhibitory	NN	O
effects	effect	NNS	O
of	of	IN	O
compounds	compound	NNS	O
,	,	,	O
14n	14n	NNS	O
,	,	,	O
14k	14k	NNS	O
,	,	,	O
14c	14c	NNS	O
,	,	,	O
14j	14j	NNS	O
,	,	,	O
13âb	13âb	CD	O
,	,	,	O
18c	18c	NNS	O
,	,	,	O
and	and	CC	O
18d	18d	NNS	O
on	on	IN	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
changes	change	NNS	O
in	in	IN	O
inflammatory	inflammatory	JJ	O
cytokine	cytokine	JJ	O
expression	expression	NN	O
,	,	,	O
casapse-1	casapse-1	NNP	O
and	and	CC	O
junction	junction	NNP	O
molecules	molecule	NNS	O
suggested	suggest	VBD	O
that	that	IN	O
anti	anti	JJ	O
-	-	JJ	O
colitis	colitis	JJ	O
effect	effect	NN	O
of	of	IN	O
the	the	DT	O
compounds	compound	NNS	O
was	be	VBD	O
associated	associate	VBN	O
with	with	IN	O
both	both	CC	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
and	and	CC	O
mucosal	mucosal	NN	O
healing	healing	NN	O
activities	activity	NNS	O
.	.	.	O

In	in	IN	O
summary	summary	NN	O
,	,	,	O
synthetic	synthetic	JJ	O
pyridinols	pyridinol	NNS	O
14n	14n	NNS	O
,	,	,	O
14k	14k	NNS	O
,	,	,	O
14c	14c	NNS	O
,	,	,	O
14j	14j	NNS	O
,	,	,	O
13b	13b	NNS	O
,	,	,	O
18c	18c	NNS	O
,	,	,	O
and	and	CC	O
18d	18d	NNS	O
compounds	compound	NNS	O
showed	show	VBD	O
strong	strong	JJ	O
inhibitory	inhibitory	JJ	O
effects	effect	NNS	O
against	against	IN	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
action	action	NN	O
in	in	IN	O
vitro	vitro	FW	O
and	and	CC	O
TNBS	TNBS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
colitis	colitis	NN	O
in	in	IN	O
vivo	vivo	NNP	O
.	.	.	O

The	the	DT	O
compound	compound	NN	O
14n	14n	NNS	O
,	,	,	O
which	which	WDT	O
showed	show	VBD	O
the	the	DT	O
highest	high	JJS	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
against	against	IN	O
colitis	colitis	NN	O
,	,	,	O
may	may	MD	O
be	be	VB	O
a	a	DT	O
promising	promising	JJ	O
lead	lead	NN	O
compound	compound	NN	O
to	to	TO	O
develop	develop	VB	O
anti	anti	JJ	O
-	-	JJ	O
IBD	ibd	JJ	O
therapeutics	therapeutic	NNS	O
.	.	.	O

